1 **Supporting Information for**

2 **The effect of combining antibiotics on resistance: A systematic**

3 **review and meta-analysis**

-
- Berit Siedentop^{1,2*}, Viacheslav N. Kachalov^{2,3}, Christopher Witzany¹, Matthias Egger^{4,5,6}, Roger D.
- $\begin{array}{c} 4 \\ 5 \\ 6 \end{array}$
- 6 Kouyos^{2,3†}, Sebastian Bonhoeffer^{1*†}
7 ¹ Institute of Integrative Biology, Dep Zurich, Switzerland ¹ Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich,
- 8 Zurich, Switzerland
9 2 Division of Infectio
- 9 2 Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University 10 of Zürich, Zürich, Switzerland
- 10 of Zürich, Zürich, Switzerland
11 3 Institute of Medical Virology,
- ³ Institute of Medical Virology, University of Zurich, Zurich, Switzerland
12 ⁴ Institute of Social and Preventive Medicine (ISPM), University of Bern
- ⁴ Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

⁵ Population Health Sciences, University of Bristol, Bristol, UK
-
- ⁵ Population Health Sciences, University of Bristol, Bristol, UK
14 ⁶ Centre for Infectious Disease Epidemiology and Research, Fa ⁶ Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences,
15 University of Cape Town, Cape Town, South Africa
- 15 University of Cape Town, Cape Town, South Africa
16 These authors contributed equally
- 16 These authors contributed equally
17 *Berit Siedentop, Sebastian Bonhoe
- *Berit Siedentop, Sebastian Bonhoeffer
- 18
- 19
- 20

21

22

-
- 24
- 25
- 26
- 27

28 **Supporting Information Text**

29 **1. Definitions of resistance development**

30 To measure resistance development in patients with standard clinical routines is
31 challenging. Without antibiotic pressure a resistant strain might be present within the p 31 challenging. Without antibiotic pressure a resistant strain might be present within the patient at 32 low frequency and might not be detected with a culture due to detection limits. With antibiotic 32 low frequency and might not be detected with a culture due to detection limits. With antibiotic
33 treatment the frequency of this resistant strain might rise and therefore the strain might be 33 treatment the frequency of this resistant strain might rise and therefore the strain might be 34 detected in a follow-up culture. In this case resistance did not develop *de novo*, but it is diff 34 detected in a follow-up culture. In this case resistance did not develop *de novo*, but it is difficult to 35 distinguish this case from an event where it did. Furthermore, the genetic relatedness is not 36 always checked between initial and follow-up cultures, meaning that the resistant bacterium 36 always checked between initial and follow-up cultures, meaning that the resistant bacterium at a
37 follow-up culture could have been also transmitted from a different body cite or from other 37 follow-up culture could have been also transmitted from a different body cite or from other
38 infection sources. To give a more comprehensive overview of how antibiotic treatment stra 38 infection sources. To give a more comprehensive overview of how antibiotic treatment strategies 39 might affect the resistance development, we therefore choose to present the results of two 39 might affect the resistance development, we therefore choose to present the results of two
40 resistance estimates. A broader estimate, acquisition of resistance, and a stricter estimate 40 resistance estimates. A broader estimate, acquisition of resistance, and a stricter estimate *de novo* emergence of resistance, where the latter is a subset of the former. A patient is considered
42 to have acquired resistance, if at the follow-up culture there has been a resistant (as defined by 42 to have acquired resistance, if at the follow-up culture there has been a resistant (as defined by 43 the study authors) bacterial species detected, that has not been detected in the baseline culture 43 the study authors) bacterial species detected, that has not been detected in the baseline culture.
44 A patient is considered to have *de novo* emergence of resistance, if at follow-up up culture a 44 A patient is considered to have *de novo* emergence of resistance, if at follow-up up culture a 45 resistant bacterium was detected, that has already been detected at the baseline culture, but 46 sensitive. De novo emergence of resistance is nested in the definition of acquisition of resistance 46 sensitive. *De novo* emergence of resistance is nested in the definition of acquisition of resistance.
47 In acquisition of resistance we account for bacteria at low abundance that could have been 47 In acquisition of resistance we account for bacteria at low abundance that could have been
48 Inteady present at the beginning of treatment, but not detected at screening. In this definitio 48 already present at the beginning of treatment, but not detected at screening. In this definition it is
49 impossible to distinguish though whether the bacteria already colonised the patient or whether 49 impossible to distinguish though, whether the bacteria already colonised the patient or whether 50 the patient was newly infected by an external source during treatment and when the bacterium 50 the patient was newly infected by an external source during treatment and when the bacterium 51 developed resistance. We also included the stricter definition de novo emergence of resistance 51 developed resistance. We also included the stricter definition *de novo* emergence of resistance. 52 For *de novo* emergence we only consider cases where a sensitive bacterium was cultured at 53 baseline. In this definition it is less likely to count cases, where resistant bacteria were transmitted
54 from an external source, as a de novo emergence event. But there are cases, which are counted 54 from an external source, as a *de novo* emergence event. But there are cases, which are counted 55 as an event of *de novo* emergence of resistance, where in fact resistance did not develop newly,
56 but resistance was only selected during treatment. This could be the case when a sensitive 56 but resistance was only selected during treatment. This could be the case when a sensitive 57 bacterium was cultured at baseline and the same kind of bacterium was also present at a non-
58 detectable frequency as a resistant phenotype. Overall both resistance development definitions 58 detectable frequency as a resistant phenotype. Overall both resistance development definitions 59 have their limitations and capture slightly different impacts of antibiotic treatment on resistance.

60 In the main manuscript we showed results for the outcome acquisition of resistance and in 61 the following section the main pooled estimates for *de novo* emergence of resistance are 61 the following section the main pooled estimates for *de novo* emergence of resistance are presented.

63 **2. Main estimates for** *de novo* **emergence of resistance**

64 As for acquisition of resistance (main text figure 3), we did not identify a difference of using a
65 higher number of antibiotics in comparison to less if *de novo* emergence of resistance is higher number of antibiotics in comparison to less if *de novo* emergence of resistance is 66 considered.

67 Counterintuitively, for *Mycobacterium tuberculosis* (Mtb) – which may be regarded as the flagship

68 of antibiotic combination therapy – we could only identify two studies matching our inclusion 69 criteria via our systematic search (main text figure 3. figure $S(1)$. Since the 1950s the

69 criteria via our systematic search (main text figure 3, figure S1). Since the 1950s the

70 administration of antibiotics often changes within the Mtb treatment period (1, 2). With the early
71 establishment of changing antibiotics within the Mtb treatment period, it would be understandabl

71 establishment of changing antibiotics within the Mtb treatment period, it would be understandable,

T2 that resistance development measurements of periods with fixed antibiotic treatment, which is an

73 inclusion criterion for our review, got less frequent over the years. Therefore, the relatively small

73 inclusion criterion for our review, got less frequent over the years. Therefore, the relatively small 74 proportion of Mtb studies included in our review is not surprising. proportion of Mtb studies included in our review is not surprising.

76
77
78
79
80 Fig. S1. Forest plot of *de novo* emergence of bacterial resistance stratified by the reason antibiotics were administered. The coloring indicates the number of antibiotics that were compared in each study. A) The overall pooled LOR of all included studies. B) The pooled LOR of

80 studies with at least one antibiotic in common in the treatment arms. MRSA stands for methicillin-
81 seistant Staphylococcus aureus, MAC for Mycobacterium avium complex, and BSI for blood
82 stream infection. 81 resistant *Staphylococcus aureus*, MAC for *Mycobacterium avium* complex, and BSI for blood stream infection.

84 *2.1. All studies* 85 For all studies meeting our inclusion criteria and reporting data of *de novo* emergence of 86 resistance our estimate did not suggest a difference between using a higher number of antibiotics
87 in comparison to less. This result was in line with our main outcome acquisition of resistance. 87 in comparison to less. This result was in line with our main outcome acquisition of resistance.
88 Nevertheless, for *de novo* emergence of resistance there was a slight trend observable which 88 Nevertheless, for *de novo* emergence of resistance there was a slight trend observable which 89 suggested a benefit of using a higher number of antibiotics. However, we could not identify a
90 clear benefit (pooled OR 0.74, 95% CI 0.34 – 1.59, figure S1 A). This trend might be due to th 90 clear benefit (pooled OR 0.74, 95% CI 0.34 – 1.59, figure S1 A). This trend might be due to the 91 stricter definition of de novo emergence relative to acquisition of resistance. In the definition of 91 stricter definition of *de novo* emergence relative to acquisition of resistance. In the definition of
92 acquisition of resistance bacterial species that are different from the initial identified infecting 92 acquisition of resistance bacterial species that are different from the initial identified infecting
93 organism are included, whereas for *de novo* emergence of resistance they are not necessaril 93 organism are included, whereas for *de novo* emergence of resistance they are not necessarily
94 included. For *de novo* emergence of resistance, the efficacy of antibiotic treatment against the 94 included. For *de novo* emergence of resistance, the efficacy of antibiotic treatment against the 95 considered bacteria is therefore expected to be higher as for acquisition of resistance, as
96 antibiotics typically have a specific bacterial spectrum of activity. The model including all s 96 antibiotics typically have a specific bacterial spectrum of activity. The model including all studies 97 reporting *de novo* emergence of resistance showed a substantial amount of heterogeneity 97 reporting *de novo* emergence of resistance showed a substantial amount of heterogeneity
98 (l^2 =77%, figure S1A). (*I ²* 98 =77%, figure S1A).

99 *2.2. Studies with at least one antibiotic common to both treatment arms*

100 To compare more similar antibiotic treatments, we also estimated the effect of *de novo*

101 emergence of resistance based on studies, that had at least one antibiotic common to the 102 comparator arms. With this restriction we also did not identify a difference of using a highe 102 comparator arms. With this restriction we also did not identify a difference of using a higher 103 number of antibiotics in comparison to less, but we observed a stronger tendency of a bene

- 103 number of antibiotics in comparison to less, but we observed a stronger tendency of a benefit of 104 using a higher number of antibiotics (pooled OR 0.45, 95% CI 0.20 1.02, figure S1B). The
- 104 using a higher number of antibiotics (pooled OR 0.45, 95% CI 0.20 1.02, figure S1B). The 105 model for studies reporting *de novo* emergence of resistance, and with at least one common
- model for studies reporting *de novo* emergence of resistance, and with at least one common 106 antibiotic in the comparator arms showed still a substantial amount of heterogeneity (l^2 =73%,
- 107 figure S1B).

108 **3. Risk of bias assessment**

109 To assess the risk of bias for our two main outcomes we used the RoB 2 tool (3). The results of 110 the risk of bias assessments for acquisition, and *de novo* emergence of resistance differed only 110 the risk of bias assessments for acquisition, and *de novo* emergence of resistance differed only
111 marginally, which can be explained by the overlap of those two definitions. We defined *de novo* 111 marginally, which can be explained by the overlap of those two definitions. We defined *de novo* 112 emergence of resistance as a stricter subset of acquisition of resistance (section 1). In both cases 113 two studies were classified overall with a low risk of bias, and about 50 % percent of the studies 113 two studies were classified overall with a low risk of bias, and about 50 % percent of the studies 114 were classified overall with some concerns of bias (67% acquisition of resistance, 72 % 114 were classified overall with some concerns of bias (67% acquisition of resistance, 72 % 15
115 emergence of resistance, figure S2). The highest source of at least some concern was t 115 emergence of resistance, figure S2). The highest source of at least some concern was the 116 selection of the reported results. As development of resistance is not a typical main objective 116 selection of the reported results. As development of resistance is not a typical main objective of 117 RCTs, and since we included a large proportion of rather old studies, the resistance outcome is RCTs, and since we included a large proportion of rather old studies, the resistance outcome is 118 often not well (pre-)defined (table S1) and not presented in a systematic way, which can explain
119 the risk of bias observed in the category "selection of the reported results". Since the studies wer 119 the risk of bias observed in the category "selection of the reported results". Since the studies were 120 rather underpowered (main text: figure 2B) to detect the resistance development, missing data 120 rather underpowered (main text: figure 2B) to detect the resistance development, missing data
121 vas commonly a high risk of concern in the domain "deviations from intended interventions". The 121 was commonly a high risk of concern in the domain "deviations from intended interventions". The 122 detailed output of the risk of bias assessment using the RoB 2 tool can be found at OSF under 122 detailed output of the risk of bias assessment using the RoB 2 tool can be found at OSF under
123 the following link "https://osf.io/gwefy/?view only=f6a4c1f4c79241038b203bd03c8e1845". the following link "https://osf.io/gwefy/?view_only=f6a4c1f4c79241038b203bd03c8e1845".

126 **Fig. S2.** Risk of bias summary for the two main outcomes: A) Acquisition of resistance, B) *de* novo emergence of resistance.

128

129 **Table S1.** Justification for extraction of resistance development. The definitions of resistance
130 development are stated as given by study authors. In case no explicit definition was given, we

130 development are stated as given by study authors. In case no explicit definition was given, we 131 state a justification for extraction and indicate it with $(*)$. Note that for data extraction for the

131 state a justification for extraction and indicate it with (*). Note that for data extraction for the same
132 publications of Dekker et al. 2015 and Pogue et al. 2021 additional publications of the same publications of Dekker et al. 2015 and Pogue et al. 2021 additional publications of the same
133 studies were consulted (Paul et al. 2018 (4) and Kaye et al. 2022 (5) respectively). Resistand

133 studies were consulted (Paul et al. 2018 $\overline{4}$) and Kaye et al. 2022 (5) respectively). Resistance
134 breakpoints are stated in case numerical values were given in the respective studies. See table

134 breakpoints are stated in case numerical values were given in the respective studies. See table 1
135 in the main text for which antibiotics the studies tested and reported extractable resistance data. in the main text for which antibiotics the studies tested and reported extractable resistance data.

137 **4. Sensitivity analysis for main estimates**

138 To test the robustness of our main analyses, we performed sensitivity analyses based on the nodel choice and the risk of bias.

model choice and the risk of bias.

140 *4.1. Model choice*

141 For our analyses we applied the random effects model 4 described in Jackson et al (48) using the 142 R package metafor (49). To test the robustness of our estimates to the model choice we reran the

142 R package *metafor* (49). To test the robustness of our estimates to the model choice we reran the 143 main analyses with the conventional random effects model (model 1 in Jackson et al (48)) and an

143 main analyses with the conventional random effects model (model 1 in Jackson et al (48)) and an
144 corresponding Bavesian version of model 4 in Jackson et al (48). For the sensitivity analyses the

144 corresponding Bayesian version of model 4 in Jackson et al (48). For the sensitivity analyses the 145 R packages metafor (49), and MetaStan(50) with default settings were used. We observe that our

145 R packages *metafor* (49), and MetaStan(50) with default settings were used. We observe that our
146 estimates are typically robust to model choice (figures S3, S4). Only for *P. aeruginousa* our

146 estimates are typically robust to model choice (figures S3, S4). Only for *P. aeruginousa* our

- 147 estimate was not robust in our sensitivity anlaysis, where the alternative two approaches showed
148 on harm or benefit of using a higher number of antibiotics (figure S3).
- no harm or benefit of using a higher number of antibiotics (figure S3).
- 149

151 **Fig. S3.** Sensitivity analysis based on model choice for the two main outcomes: A) acquisition of 152 resistance, B) de novo emergence of resistance. Shown are the frequentist model estimates of 152 resistance, B) *de novo* emergence of resistance. Shown are the frequentist model estimates of 153 model 1, and model 4 presented in Jackson et al (48) and a Bayesian estimate of model 4. UTI 153 model 1, and model 4 presented in Jackson et al (48) and a Bayesian estimate of model 4. UTI
154 stands for urinary tract infection, MRSA for methicillin-resistant Staphylococcus aureus, and MA 154 stands for urinary tract infection, MRSA for methicillin-resistant *Staphylococcus aureus*, and MAC for *Mycobacterium avium* complex.

158 **Fig. S4.** Sensitivity analysis based on model choice for the two main outcomes restricted to 159 studies with at least one common antibiotic in the comparator arms: A) acquisition of resista 159 studies with at least one common antibiotic in the comparator arms: A) acquisition of resistance,
160 B) de novo emergence of resistance. Shown are the frequentist model estimates of model 1, and 160 B) *de novo* emergence of resistance. Shown are the frequentist model estimates of model 1, and 161 model 4 presented in Jackson et al (48) and a Bayesian estimate of model 4. model 4 presented in Jackson et al (48) and a Bayesian estimate of model 4.

162

163 *4.2. Impact of risk of bias*

164 To assess the impact of risk of bias on our estimates, we reran the main analyses stratifying
165 according to the overall risk of bias. For studies classified with an overall high risk of bias our 165 according to the overall risk of bias. For studies classified with an overall high risk of bias our 166 analysis shows that for acquisition of resistance using a lower number of antibiotics shows a analysis shows that for acquisition of resistance using a lower number of antibiotics shows a

- 167 benefit (pooled OR 4.45, 95% CI 1.67 11.81; l^2 =57, table S2). We did not observe any
- 168 difference of using a higher number of antibiotics in comparison to less in resistance development 169 when grouping the rest of the studies according to their risk assessment (table S2). Nevertheless,
- 169 when grouping the rest of the studies according to their risk assessment (table S2). Nevertheless, 170 with less risk of bias administering a higher number of antibiotics seemed to perform better in
- 170 with less risk of bias administering a higher number of antibiotics seemed to perform better in 171 comparison to less. However, no clear benefit could be determined (table S2). This observatic
- 171 comparison to less. However, no clear benefit could be determined (table S2). This observation
172 additionally supports that RCTs with resistance development as a main objective, and therefore
- 172 additionally supports that RCTs with resistance development as a main objective, and therefore
173 potentially decreasing the risk of bias, are needed to understand the impact of different treatmen 173 potentially decreasing the risk of bias, are needed to understand the impact of different treatment 174 strategies on antibiotic resistance outcomes. strategies on antibiotic resistance outcomes.
- 175

176 **Table S2.** Summary of the results of the sub-group analyses stratifying according to the overall 177 risk of bias for the two main outcomes. Note that the listing of eligible studies also includes

177 risk of bias for the two main outcomes. Note that the listing of eligible studies also includes
178 studies reporting zero cases in both treatment arms and were therefore not included in the 178 studies reporting zero cases in both treatment arms and were therefore not included in the 179 statistical analysis. statistical analysis.

180

181 **5. Publication bias**

182 In the study protocol we stated that we will test for publication bias via visual inspection of the 183 funnel plots and by Egger's test. As Egger's test can have problems with false-positive results 183 funnel plots and by Egger's test. As Egger's test can have problems with false-positive results for 184
184 dichotomous outcomes, we used a modified version of the Egger's test, i.e. the Harbord's test dichotomous outcomes, we used a modified version of the Egger's test, i.e. the Harbord's test

185 (51).
186 Neith 186 Neither the visual inspection of the funnel plots (figure S5), nor Harbord's tests gave an indication 187 for a publication bias for our two main outcomes acquisition, and de novo emergence of

- 187 for a publication bias for our two main outcomes acquisition, and *de novo* emergence of 188 resistance (acquisition of resistance: Harbord's: $p = 0.28$; *de novo* emergence of resistance 188 resistance (acquisition of resistance: Harbord's: p = 0.28; *de novo* emergence of resistance:
- Harbord's: $p = 0.51$).

192 **Fig. S5.** Funnel plots for the two main outcomes: A) acquisition of resistance, B) *de novo*

emergence of resistance.

194

195 **6. Sub-group analyses**

196 The performance of an antibiotic treatment strategy to minimise resistance spread is not only 197 dependent on the number of antibiotics administered. In our main estimates we found a 197 dependent on the number of antibiotics administered. In our main estimates we found a
198 substantial amount of heterogeneity (main text: figure 3: figure S1), which is an indication 198 substantial amount of heterogeneity (main text: figure 3; figure S1), which is an indication that 199 additional factors might be important to consider in a statistical model. In the following we first 199 additional factors might be important to consider in a statistical model. In the following we first 200 present the results of in the study protocol pre-defined subgroup analyses and afterwards 200 present the results of in the study protocol pre-defined subgroup analyses and afterwards
 201 additional post-hoc subgroup analyses. One must consider that the results are mainly bas 201 additional post-hoc subgroup analyses. One must consider that the results are mainly based on
202 underpowered studies (main text: figure 2 B), and that in the subgroup analyses the number of 202 underpowered studies (main text: figure 2 B), and that in the subgroup analyses the number of 203
203 included studies decreases. Therefore, the results of the subgroup analyses should be 203 included studies decreases. Therefore, the results of the subgroup analyses should be considered with care.

205 *6.1. Predefined in study protocol*

206 The results of our subgroup-analyses for the outcome acquisition of resistance and de novo
207 emergence of resistance are summarised in table S3 and table S4 respectively. The rational 207 emergence of resistance are summarised in table S3 and table S4 respectively. The rationale for 208 carrying out the predefined sub-group analyses are explained in the following subsections.

- carrying out the predefined sub-group analyses are explained in the following subsections.
- 209

210 **Table S3.** Summary of the results of the predefined sub-group analyses for the outcome 211 acquisition of resistance. Note that the listing of eligible studies also includes studies reporting 212 zero cases in both treatment arms, which are not included in the statistical analysis. zero cases in both treatment arms, which are not included in the statistical analysis.

214 **Table S4.** Summary of the results of the predefined sub-group analyses for the outcome *de novo*

 215 emergence of resistance. Note that the listing of eligible studies also includes studies reporting

216 zero cases of resistance in both treatment arms, which were therefore not included in the

215 emergence of resist
216 zero cases of resist
217 statistical analysis.

218
219

219 **6.1.1.Number of antibiotics administered** 220 In our systematic review we did not predefine a fixed number of antibiotics to compare. We 221 rather aimed to investigate whether there is a general trend of a treatment strategy with a higher 222 number of antibiotics performing better than one with less antibiotics with respect to resistance 222 number of antibiotics performing better than one with less antibiotics with respect to resistance
223 development. One can imagine though, that the magnitude of this trend might vary depending o 223 development. One can imagine though, that the magnitude of this trend might vary depending on
224 the number of antibiotics compared. For example, if resistance against the used antibiotics is 224 the number of antibiotics compared. For example, if resistance against the used antibiotics is 225 likely to be encountered in the population, a comparison of one versus two antibiotics might g 225 likely to be encountered in the population, a comparison of one versus two antibiotics might give
226 different results than two versus three. In the 1960s for Mtb the number of antibiotics was for 226 different results than two versus three. In the 1960s for Mtb the number of antibiotics was for
227 instance increased to three antibiotics at the initial treatment phase, due to the finding that 227 instance increased to three antibiotics at the initial treatment phase, due to the finding that
228 primary resistance can be encountered for one drug but rarely to two or three antibiotics (2 228 primary resistance can be encountered for one drug but rarely to two or three antibiotics (2, 52, 22)
229 53). On one hand, if the number of antibiotics used is rather high in both treatment arms, there 53). On one hand, if the number of antibiotics used is rather high in both treatment arms, there
230 might be no difference in resistance development detected as the treatment period might be to 230 might be no difference in resistance development detected as the treatment period might be too 231 short to observe a relevant effect. On the other hand, if the treatment period is rather long, there 231 short to observe a relevant effect. On the other hand, if the treatment period is rather long, there
232 might also not be an efficient effect detectable when a low number of antibiotics is compared and 232 might also not be an efficient effect detectable when a low number of antibiotics is compared and
233 the timespan between follow-up cultures is long. We considered the effect of treatment length, 233 the timespan between follow-up cultures is long. We considered the effect of treatment length, 234 and length of follow-up on our estimates later in the meta-regression and multi-model inference 235 (section 7).
236 We id

 236 We identified three studies comparing one versus three antibiotics, but two of them had zero 237 events for both comparator arms. We included two Mtb studies in our review comparing three 237 events for both comparator arms. We included two Mtb studies in our review comparing three
238 versus four antibiotics, but both had zero events in the comparator arms. For the estimates on 238 versus four antibiotics, but both had zero events in the comparator arms. For the estimates one
239 versus two antibiotics and two versus three antibiotics we did not identify a difference of using a 239 versus two antibiotics and two versus three antibiotics we did not identify a difference of using a 240 higher number of antibiotics in comparison to less, and substantial heterogeneity was observed 241 (tables S3, S4). Nevertheless, for the estimate two versus three antibiotics there was a beneficial (242) trend for using a higher number of antibiotics observable. However, no clear benefit could be 242 trend for using a higher number of antibiotics observable. However, no clear benefit could be
243 determined (tables S3, S4). This might indicate that in general a higher number of antibiotics 243 determined (tables S3, S4). This might indicate that in general a higher number of antibiotics in 244 treatments is beneficial.
245 **6.1.2.Administr**

245 **6.1.2.Administration of additional non-antibiotic drugs** 246 In our inclusion criteria we allowed the administration of additional non-antibiotic drugs,
247 which potentially could also affect the resistance outcome due to faster cure of patients, or by 247 which potentially could also affect the resistance outcome due to faster cure of patients, or by
248 specifically supporting the activity of antibiotics, as e.g. beta-lactam-inhibitors. To test the effect 248 specifically supporting the activity of antibiotics, as e.g. beta-lactam-inhibitors. To test the effect of
249 the administration of additional non-administered antibiotics, we performed a sub-group analysis 249 the administration of additional non-administered antibiotics, we performed a sub-group analysis
250 based on whether a study administered additional non-antibiotic drugs or not. Notably, in our 250 based on whether a study administered additional non-antibiotic drugs or not. Notably, in our
251 studies the additional non-antibiotics were always administered in both treatment arms. 251 studies the additional non-antibiotics were always administered in both treatment arms.
252 Considering if additional non-antibiotic drugs were administered or not did not show any 252 Considering if additional non-antibiotic drugs were administered or not did not show any harm or
253 benefit on the resistance outcome whether a higher number of antibiotics was used or a lower 253 benefit on the resistance outcome whether a higher number of antibiotics was used or a lower
254 pumber (tables S3, S4). A few studies allowed the administration of additional non-antibiotics. 254 number (tables S3, S4). A few studies allowed the administration of additional non-antibiotics, but
255 they were not a fixed part of the treatment regime. Also, in those studies we did not identify a 255 they were not a fixed part of the treatment regime. Also, in those studies we did not identify a harm or benefit (tables S3, S4).

257 **6.1.3.Usage of same dosage of antibiotics common to both treatment arms**

258 Not only the number of total antibiotics might determine the efficacy of a treatment, but also
259 the dosage of antibiotics. To compare more similar treatments, we estimated the pooled OR for 259 the dosage of antibiotics. To compare more similar treatments, we estimated the pooled OR for 260 studies that administered at least one antibiotic common to both treatment arms, and where 261 additionally the antibiotics that were common were administered with the same dosage. We 261 additionally the antibiotics that were common were administered with the same dosage. We 262 observed that in most cases if at least one common antibiotic was administered, their dosage was 263 the same (78% acquisition of resistance, 86% emergence of resistance). Therefore, it is not 263 the same (78% acquisition of resistance, 86% emergence of resistance). Therefore, it is not 264 surprising that we observe, in line with the analysis "at least one antibiotic common to both 265 treatment arms" (main text: figure 3B, figure S1 B), no difference in using a higher number of 266 antibiotics in comparison to less to reduce resistances (tables S3, S4). In both cases we 266 antibiotics in comparison to less to reduce resistances (tables S3, S4). In both cases we
267 observed a substantial amount of heterogeneity, which indicates that further factors might 267 observed a substantial amount of heterogeneity, which indicates that further factors might play a
268 role for explaining the observed resistance differences. 268 role for explaining the observed resistance differences.
269 **6.1.4. Required comorbidity at study inclusic**

269 **6.1.4.Required comorbidity at study inclusion** 270 The way the immune-system reacts to an infection might potentially influence the
271 frequencies of resistances observed (54). Therefore, we tested whether studies that co 271 frequencies of resistances observed (54). Therefore, we tested whether studies that considered
272 patients with a comorbidity, assuming that the immune system is to some extent compromised, 272 patients with a comorbidity, assuming that the immune system is to some extent compromised,
273 show a different trend of resistance development in comparison to studies where no comorbidity 273 show a different trend of resistance development in comparison to studies where no comorbidity
274 vas required for study inclusion. For this analysis we considered studies, that had comorbidities 274 was required for study inclusion. For this analysis we considered studies, that had comorbidities 275 as a requirement for study entry. We could not identify a difference of using a higher number of 276 antibiotics in comparison to less for both main outcomes, and regardless of comorbidity status a 276 antibiotics in comparison to less for both main outcomes, and regardless of comorbidity status at 277 study entrance (tables S3, S4). 277 study entrance (tables S3, S4).
278 **6.1.5.Study was cond**i

278 **6.1.5.Study was conducted in an ICU** 279 Another way to test the potential role of the immune system is by severity of illness,
280 approximated whether the study population was treated within an ICU or not. We were no 280 approximated whether the study population was treated within an ICU or not. We were not able to
281 link on a patient level the data of resistance development to the patient's ICU status. Therefore. 281 link on a patient level the data of resistance development to the patient's ICU status. Therefore,
282 ve tried to classify the ICU status per study, i.e. one status for the whole study population. We 282 we tried to classify the ICU status per study, i.e. one status for the whole study population. We
283 only identified two studies (5%) for acquisition of resistance, where the whole study population 283 only identified two studies (5%) for acquisition of resistance, where the whole study population 284 was in the ICU. We found 9 studies (21%), where no patient was treated in the ICU. For the rest 285 of the studies the population could either be mixed (14%), or no information was confidentially 285 of the studies the population could either be mixed (14%), or no information was confidentially 286 extractable (60%). Since the ICU status on a study level seemed to be an uninformative proxy. 286 extractable (60%). Since the ICU status on a study level seemed to be an uninformative proxy, 287 we decided not to perform sub-group analyses for this factor. 287 we decided not to perform sub-group analyses for this factor.
288 6.1.6.Gram-status

288 **6.1.6.Gram-status** 289 The gram status of a bacterium may potentially determine how effective an antibiotic, or an 290 antibiotic combination is. Differences between gram-negative and gram-positive bacteria such as
291 distinct bacterial surface organisation can lead to specific intrinsic resistances of gram-negative 291 distinct bacterial surface organisation can lead to specific intrinsic resistances of gram-negative 292 and gram-positive bacteria against antibiotics (55). These structural differences can lead to 293 varying effects of antibiotic combinations between gram-negative and gram-positive bacteria (56). 294 Additionally, plasmids play a major role in the dissemination of antibiotic resistance genes in both 295 qram-positive, and negative bacteria (57). The spread of plasmids differs considerably between 295 gram-positive, and negative bacteria (57). The spread of plasmids differs considerably between
296 gram-positive bacteria and gram-negative bacteria (58). These structural differences could 296 gram-positive bacteria and gram-negative bacteria (58). These structural differences could
297 influence the performance of antibiotic treatment strategies. To test the influence of the gra 297 influence the performance of antibiotic treatment strategies. To test the influence of the gram-
298 status on our estimates we performed sub-group analyses with studies, that focused only on 298 status on our estimates we performed sub-group analyses with studies, that focused only on 299 measurements of gram-negative bacteria, gram-positive, or both. We classified the gram-status
300 on a study level as we could not link the gram-status and resistance development on a patient 300 on a study level as we could not link the gram-status and resistance development on a patient 301 level. 301 level.
302

302 When selecting for studies that either focus on gram-negative, or gram-positive we did not 303 identify a difference in using a higher number of antibiotics in comparison to less for both main 304 outcomes (tables S3, S4). For the subgroup analysis including studies with the focus on both 304 outcomes (tables S3, S4). For the subgroup analysis including studies with the focus on both 305 gram-negative and positive bacteria the treatment strategy with a lower number of antibiotics 306 showed a benefit for the main outcome acquisition of resistance (pooled OR 3.38, 95% Cl 1.0 306 showed a benefit for the main outcome acquisition of resistance (pooled OR 3.38, 95% CI 1.08 – 307 – 307 – 307 – 307 – 307 – 307 – 307 – 40.58; l^2 =44%, table S3). However, for *de novo* emergence of resistance we d 10.58; *I ²* 307 =44%, table S3). However, for *de novo* emergence of resistance we did not identify a 308 difference (pooled OR 3.35, 95% CI 0.67 – 16.71; $l^2 = 47$ %, table S4) It seems, that acquisition of 309 resistance is more sensible to the restriction on which gram-status is considered. This might be 310 due to the broader definition of acquisition of resistance as it is more sensitive to resistance 310 due to the broader definition of acquisition of resistance as it is more sensitive to resistance 311 changes in the microbial community. If a treatment is targeted against a specific pathogen. 311 changes in the microbial community. If a treatment is targeted against a specific pathogen, e.g. a
312 gram-positive bacterium, other bacteria of the microbiota are exposed to the treatment as well. 312 gram-positive bacterium, other bacteria of the microbiota are exposed to the treatment as well.
313 Some bacteria of the microbiota might be more intrinsically resistant against the administered Some bacteria of the microbiota might be more intrinsically resistant against the administered

314 antibiotics, e.g. a gram-negative bacterium, and are therefore more likely to develop resistance.
315 With acquisition of resistance, we might detect such effects. 315 With acquisition of resistance, we might detect such effects.
 316 **6.1.7.All resistances not only against administer**

316 **6.1.7.All resistances not only against administered antibiotics** 317 Antibiotic resistances can be acquired by plasmids, which in a clinical context often confer
318 resistances against multiple antibiotics (59-61). Therefore, we aimed to test, whether a higher 318 resistances against multiple antibiotics (59-61). Therefore, we aimed to test, whether a higher 319 number of antibiotics also leads to resistance against a higher number of antibiotics, considering 320 both resistances of antibiotics that were administered and ones that were not. For acquisition of 320 both resistances of antibiotics that were administered and ones that were not. For acquisition of 321 resistance, we only identified seven studies that measured resistances also against non-321 resistance, we only identified seven studies that measured resistances also against non-
322 administered drugs. Only three of those studies have non-zero events. For de novo emer 322 administered drugs. Only three of those studies have non-zero events. For *de novo* emergence of 323 resistance, we identified four studies measuring resistances against non-administered antibiotics,
324 vere two of them have non-zero events in both treatment arms. Due to the small number of 324 were two of them have non-zero events in both treatment arms. Due to the small number of 325 studies identified and even smaller number of studies having non-zero resistance events, we 325 studies identified and even smaller number of studies having non-zero resistance events, we only 326 present the estimates of the resistances against non-administered antibiotics (sections 9.6 and 326 present the estimates of the resistances against non-administered antibiotics (sections 9.6 and 327 9.7).

328 **6.1.8.Only resistances of antibiotics common to treatments arms** 329 To estimate how the same antibiotics performed in the different treatment arms we 330 performed a subgroup-analysis only considering resistance against antibiotics common to both 331 treatment arms. For both main outcomes we observed that if we only consider resistances of common antibiotics the treatment arm with the higher number of antibiotics showed a benefit 332 common antibiotics the treatment arm with the higher number of antibiotics showed a benefit 333 (acquisition of resistance: pooled OR 0.39, 95% CI 0.18 – 0.81; l^2 =76%, table S3; emergence 333 (acquisition of resistance: pooled OR 0.39, 95% CI 0.18 – 0.81; $l^2 = 76$ %, table S3; emergence of 334 resistance: pooled OR 0.32, 95% CI 0.16 - 0.66; l^2 =59% table S4). Consequently, we can 335 conclude that for a specific antibiotic less resistances will develop in a treatment arm with a 336 higher number of antibiotics. 336 higher number of antibiotics.
337 As the studies included

337 As the studies included in our meta-analysis often did not quantify the resistance outcome 338 for all antibiotics administered in a treatment arm it is harder to assess the full resistance burden
339 of the antibiotic treatments systematically. One could arque that due to the higher number of 339 of the antibiotic treatments systematically. One could argue that due to the higher number of 340 antibiotics given in one treatment arm, one would also observe in total a higher resistance bu 340 antibiotics given in one treatment arm, one would also observe in total a higher resistance burden
341 in that arm. This possible effect could be magnified dependent on the potency of antibiotics. If a 341 in that arm. This possible effect could be magnified dependent on the potency of antibiotics. If a
342 treatment arm is a combination of a low potency antibiotics, one might expect a higher chance o 342 treatment arm is a combination of a low potency antibiotics, one might expect a higher chance of
 343 resistance. The results of this sub-group analysis highlight once more that a systematic 343 resistance. The results of this sub-group analysis highlight once more that a systematic
344 exploration of resistance development in RCTs is important for a better understanding o 344 exploration of resistance development in RCTs is important for a better understanding of 345 resistance development during treatment and that the identity of the administered antibiot 345 resistance development during treatment and that the identity of the administered antibiotics 346 might play an important role. 346 might play an important role.
347 **6.1.9.Age of antibio**

347 **6.1.9.Age of antibiotics since conduction of the trial** 348 The prevalence of antibiotic resistance affects the treatment success. If resistance before 349 treatment is frequent in the population, then this increases the likelihood that the prescribed 350 antibiotic treatment fails for any patient. We collected data on the vear the admission of patient 350 antibiotic treatment fails for any patient. We collected data on the year the admission of patients 351 for the individual studies started and the year antibiotics became available. With the naive 351 for the individual studies started and the year antibiotics became available. With the naive
 352 assumption that the longer the antibiotic has been available before the study was conduct(352 assumption that the longer the antibiotic has been available before the study was conducted, the
353 bigher is its resistance prevalence within the population. This assumption has its weaknesses as 353 higher is its resistance prevalence within the population. This assumption has its weaknesses as 354 antibiotics are used with different intensities over the years and their local pattern of use might 354 antibiotics are used with different intensities over the years and their local pattern of use might 355 vary. However, such data are more difficult to retrieve. Hence, the years an antibiotic was 355 vary. However, such data are more difficult to retrieve. Hence, the years an antibiotic was
356 available until the trial started is a simple first approximation to investigate resistance prev

356 available until the trial started is a simple first approximation to investigate resistance prevalence.
357 fit the studies did not state the year the trial started, we extracted the publication year. For If the studies did not state the year the trial started, we extracted the publication year. For the availability of antibiotics, we used the older of the two dates available on DrugBank (62) and DrugCentral (63) (DrugBank: marketing start , DrugCentral: approvals).

In the following we present the subgroup analyses, where we classify in which comparator 361 arm the youngest antibiotic is administered. We did not detect a harm or benefit of using a higher
 362 or lower number of antibiotics when stratifying, and observed in all subgroup analyses at least a 362 or lower number of antibiotics when stratifying, and observed in all subgroup analyses at least a 363 substantial amount of heterogeneity (table S3, table S4).

363 substantial amount of heterogeneity (table S3, table S4). 364 Furthermore, we performed subgroup analyses stratifying according to the mean age of 365 antibiotics in a treatment arm, and the oldest antibiotic of the treatment arm. For those analyses 366 we also did not identify a difference of using a higher number of antibiotics over fewer. It could be 366 we also did not identify a difference of using a higher number of antibiotics over fewer. It could be 367 that our approximation is too simplified to estimate the potential effect. 367 that our approximation is too simplified to estimate the potential effect.
368 6.1.10. No antibiotics common to treatment arms

368 **6.1.10. No antibiotics common to treatment arms**

369 In the main analyses we presented the estimates for all studies, and studies, which
370 administered at least one antibiotic common to the treatment arms. Here in the suppleme 370 administered at least one antibiotic common to the treatment arms. Here in the supplement we
371 present the resistance estimates for less comparable treatments, i.e. for studies, whose treatme 371 present the resistance estimates for less comparable treatments, i.e. for studies, whose treatment 372 arms had no antibiotics in common. For those studies we observed for both main outcomes a 372 arms had no antibiotics in common. For those studies we observed for both main outcomes a
373 trend favouring the treatment arm with fewer antibiotics (acquisition of resistance: pooled OR 373 trend favouring the treatment arm with fewer antibiotics (acquisition of resistance: pooled OR 3
374 4.73, 95% Cl 2.14 – 10.42; l^2 =37%, table S3; *de novo* emergence of resistance: pooled OR 3 374 $-$ 4.73, 95% CI 2.14 – 10.42; l^2 =37%, table S3; *de novo* emergence of resistance: pooled OR 3.54, 375 95% CI 0.91 – 13.75; l^2 =38%, table S4). The benefit was for acquisition of resistance clear, and 376 for *de novo* emergence of resistance not. The result that if the treatment arms had no antibiotics
377 in common a lower number of antibiotics performed better than a higher number of antibiotics 377 in common a lower number of antibiotics performed better than a higher number of antibiotics
378 could be due to different potencies of antibiotics or resistance prevalences. Further, there coul 378 could be due to different potencies of antibiotics or resistance prevalences. Further, there could 379 be a bias to combine less potent antibiotics or antibiotics with higher resistance prevalence to 379 be a bias to combine less potent antibiotics or antibiotics with higher resistance prevalence to 380 ensure treatment efficacy, which could lead to higher chances to detect resistances in the 380 ensure treatment efficacy, which could lead to higher chances to detect resistances in the 381 treatment arm with higher number of antibiotics. e.g. by selecting pre-existing resistance (s 381 treatment arm with higher number of antibiotics, e.g. by selecting pre-existing resistance (see
382 also section 6.1.9). This highlights once more that the identity of antibiotics may play an impor 382 also section 6.1.9). This highlights once more that the identity of antibiotics may play an important 383 role in determining whether combining antibiotics is beneficial or not with respect to resistance 383 role in determining whether combining antibiotics is beneficial or not with respect to resistance 384 development.
385 **6.1.1**1

385 **6.1.11. Systematic testing of the whole study population** 386 In our protocol we predefined that we would perform a sub-group analyses based on 387 whether the resistance data were systematically available for the whole study population or 387 whether the resistance data were systematically available for the whole study population or just a
388 subset of patients. All our included studies attempted to measure resistance data for the whole 388 subset of patients. All our included studies attempted to measure resistance data for the whole
389 study population. In some cases, more information on resistance development was reported tha 389 study population. In some cases, more information on resistance development was reported than
390 vhat we could use. In those cases, it was impossible to distinguish how many patients were 390 what we could use. In those cases, it was impossible to distinguish how many patients were
391 evaluable for the resistance outcomes, and/or how many patients developed resistances. In 391 evaluable for the resistance outcomes, and/or how many patients developed resistances. In
392 summary, we always obtained data for the whole study population, except of the missing dat 392 summary, we always obtained data for the whole study population, except of the missing data 393 cases but nevertheless we could not process all information given due to the way it was 393 cases, but nevertheless we could not process all information given due to the way it was 394 reported. The influence of missing data is assessed in the risk of bias assessment (section 3), 395 and the corresponding sensitivity analyses (section 4.2). 395 and the corresponding sensitivity analyses (section 4.2).
 396 6.2. Post-hoc subaroup analyses

396 **6.2. Post-hoc subgroup analyses**

397 **6.2.1.Additional administration of antibiotics** 398 During our selection process of studies, we realised that some studies allowed the addition
399 of further antibiotics to the assigned treatments, if necessary, whereas others explicitly stated no 399 of further antibiotics to the assigned treatments, if necessary, whereas others explicitly stated no
400 other antibiotics than the assigned ones are given during the treatment phase. For a large 400 other antibiotics than the assigned ones are given during the treatment phase. For a large 401 proportion of all included studies, we could not extract whether additional antibiotics were a 401 proportion of all included studies, we could not extract whether additional antibiotics were allowed 402 or not (62%). As we cannot rule out that in those studies no additional antibiotics were 402 or not (62%). As we cannot rule out that in those studies no additional antibiotics were 403 administered, we decided to include studies where additional antibiotics are allowed. T 403 administered, we decided to include studies where additional antibiotics are allowed. To check 404 the impact of this decision we performed a sub-group analyses for those studies, where 404 the impact of this decision we performed a sub-group analyses for those studies, where
405 information of administration of additional antibiotics was given. We identified 12 studies 405 information of administration of additional antibiotics was given. We identified 12 studies, which
406 allowed the administration of additional antibiotics, but only at most seven studies could be allowed the administration of additional antibiotics, but only at most seven studies could be 407 included in the statistical analyses as the other trials reported zero cases in both treatment arms 408 (14. 17. 19. 23. 30) (tables S5. S6). We identified three studies explicitly excluding additional 408 (14, 17, 19, 23, 30) (tables S5, S6). We identified three studies explicitly excluding additional 409 antibiotics, however the statistical analyses is based on two studies as one reported zero cases in 410 both treatment arms (16) (tables S5, S6). Therefore, the impact of allowing the administration of 410 both treatment arms (16) (tables S5, S6). Therefore, the impact of allowing the administration of 411 additional antibiotics, if necessary, on our overall estimates was difficult to infer. additional antibiotics, if necessary, on our overall estimates was difficult to infer.

412

413 **Table S5.** Summary of the results of the post-hoc sub-group analyses for the outcome acquisition 414 of resistance. Note that the listing of eligible studies also includes studies reporting zero cases in 415 both treatment arms and were therefore not included in the statistical analysis. both treatment arms and were therefore not included in the statistical analysis.

417 **Table S6.** Summary of the results of the post-hoc sub-group analyses for the outcome *de novo*

418 emergence of resistance. Note that the listing of eligible studies also includes studies reporting
419 zero cases in both treatment arms and were therefore not included in the statistical analysis.

zero cases in both treatment arms and were therefore not included in the statistical analysis.

Sub-group Analysis	OR (95% CI)	Study heterogeneity $(I^2; \tau^2)$	Eligible studies
Additional administration of antibiotics:			
Allowed	$0.95(0.59-1.51)$	3% ; 0.01	$(12, 14, 17, 19, 23, 24, 30, 36-39)$
Prohibited	$0.19(0.04 - 0.98)$	57%; 0.79	(16, 22, 47)
Pre-resistance against non-administered antibiotics required at study inclusion:			
Required	$1.07(0.53 - 2.18)$	17%; 0.10	$(12, 14, 19, 33, 36-38, 44)$
No	$0.63(0.23-1.68)$	78%: 2.57	(6-10, 13, 15-17, 20-27, 29, 30, 32, 34, 39, 42, 43, 47)
Way of antibiotic administration:			
Orally	$0.37(0.11 - 1.23)$	69%; 1.96	(6-8, 10, 13, 22, 23, 25, 26, 32, 43, 44, 47)
Intravenously	$1.82(0.64 - 5.18)$	66%; 0.90	(12, 14, 16, 17, 21, 24, 27, 37, 38, 42)
Different ways of administration in the treatment arms	$2.12(0.35-12.79)$	1% ; 0.01	(20, 34, 36)

⁴²⁰

421
422

422 **6.2.2.Pre-resistance against non-administered antibiotics**

423 Some of the studies we included were focused on the treatment of resistant pathogens.
424 Therefore, we tested whether carriage of resistance against non-administered antibiotics migles 424 Therefore, we tested whether carriage of resistance against non-administered antibiotics might
425 affect the development of resistance against administered antibiotics. We identified eight studie 425 affect the development of resistance against administered antibiotics. We identified eight studies 426 requiring pre-resistance, of which five had non-zero events in both treatment arms. For both 426 requiring pre-resistance, of which five had non-zero events in both treatment arms. For both
427 studies requiring pre-resistance and no pre-resistance, we could not identify a trend favourin 427 studies requiring pre-resistance and no pre-resistance, we could not identify a trend favouring
428 more or less antibiotics (tables S5, S6). As multi-drug resistance is an increasing concern it is 428 more or less antibiotics (tables S5, S6). As multi-drug resistance is an increasing concern it is 429 important to understand if the optimal treatment strategy for pre-resistant pathogens might differ 430 from the one of sensitive pathogens. However, the data of our meta-analysis are not sufficient to 431 answer this question. 431 answer this question.
432 6.2.3. Way of

432 **6.2.3.Way of antibiotic administration** 433 The way how antibiotics are administered, e.g. intravenously (IV) or orally, could also impact 434 the development of antibiotic resistance due to different pharmacokinetics and potential differing 434 the development of antibiotic resistance due to different pharmacokinetics and potential differing
435 antibiotic bioavailability (64). Therefore, we stratified our studies according to the way antibiotics 435 antibiotic bioavailability (64). Therefore, we stratified our studies according to the way antibiotics
436 were administered: orally, or IV in both treatment arms, or the way of administration differed in th 436 were administered: orally, or IV in both treatment arms, or the way of administration differed in the 437 treatment arms. We could not identify a harm or benefit in the sub-group analyses of using a 437 treatment arms. We could not identify a harm or benefit in the sub-group analyses of using a
438 bigher or a lower number of antibiotics (tables S5, S6). higher or a lower number of antibiotics (tables S5, S6).

439 **7. Meta-regressions and multi-model inference**

Additionally, to the subgroup analyses we also performed meta-regressions for the exploration of 441 the importance of factors potentially affecting our main outcomes. For the meta-regression

442 models we used the conventional random effects model (model 1 in Jackson et al (48)) due to 443 convergence issues with model 4 and since our sensitivity analysis of the main outcomes show

- 443 convergence issues with model 4 and since our sensitivity analysis of the main outcomes showed
444 tvpically robustness to the model choice (section 4). With performing meta-regressions, we were
- 444 typically robustness to the model choice (section 4). With performing meta-regressions, we were
445 able to include continuous covariables such as treatment length, and by multi model inference we
- able to include continuous covariables such as treatment length, and by multi model inference we
446 could obtain parameter estimates averaged over a set of models. The set of possible models was
- 446 could obtain parameter estimates averaged over a set of models. The set of possible models was
447 erstricted to meta-regression models with up to two covariables and no interaction terms to avoid 447 restricted to meta-regression models with up to two covariables and no interaction terms to avoid
448 overfitting. We performed multi-model inference with the R package *MuMIn* (version 1.46) (65).
- 448 overfitting. We performed multi-model inference with the R package *MuMIn* (version 1.46) (65).
- 449 For the multi-model inference all meta regression models of the set of possible models were
450 simulated. Following a model selection approach using the Akaike information criterion (AIC)
- 450 simulated. Following a model selection approach using the Akaike information criterion (AIC)
451 model, the AIC value for each model was calculated. The AIC is a measure of fit, which is bas 451 model, the AIC value for each model was calculated. The AIC is a measure of fit, which is based
452 on the log-likelihood function, and the number of unknown model parameters. Smaller AIC values 452 on the log-likelihood function, and the number of unknown model parameters. Smaller AIC values
453 are assigned to better model fits. In addition to the AIC value, we calculated the AIC differences
- are assigned to better model fits. In addition to the AIC value, we calculated the AIC differences
454 (AAIC) between each model and the model with the lowest AIC value. With AAIC we calculated 454 (∆AIC) between each model and the model with the lowest AIC value. With ∆AIC we calculated 455 the Akaike weights, which can be interpreted as the probability a model is the best of the given 455 the Akaike weights, which can be interpreted as the probability a model is the best of the given
456 set of models and data. With the full model approach, we then calculated the model averaged 456 set of models and data. With the full model approach, we then calculated the model averaged
457 coefficients, which are estimates weighted by the Akaike weights and averaged over the whole 457 coefficients, which are estimates weighted by the Akaike weights and averaged over the whole
458 set of possible models (full model average). For the interested reader further, detailed information 458 set of possible models (full model average). For the interested reader further, detailed information 459
459 can be found in literature about multi-model inference (66-68).
- 459 can be found in literature about multi-model inference (66-68).
460 The covariables we considered for the meta-regression include 460 The covariables we considered for the meta-regression included: (i) administration of antibiotics
- 461 common to the treatment arms, (ii) required comorbidity status at study inclusion, (iii) the year
462 difference between the youngest antibiotic in the treatment arm with a lower number of antibio 462 difference between the youngest antibiotic in the treatment arm with a lower number of antibiotics and the voungest in the treatment arm with a higher number of antibiotics. 463 and the youngest in the treatment arm with a higher number of antibiotics, (iv) the treatment 464 length, (v) the length of study/resistance follow up, (vi) gram status of bacteria with resistance 464 length, (v) the length of study/resistance follow up, (vi) gram status of bacteria with resistance
-
- 465 measurements, and (vii) the number of antibiotics administered.
466 The some cases, the treatment length of the two treatment arms w 166 In some cases, the treatment length of the two treatment arms within a study were of different 467 Iength, in those cases we took as the treatment length covariable the average treatment time of length, in those cases we took as the treatment length covariable the average treatment time of 468 both treatment arms. As the treatment times between treatment arms did not vary a lot, we did
469 on explore those differences further. Furthermore, we wanted to consider the age of antibiotics 469 not explore those differences further. Furthermore, we wanted to consider the age of antibiotics
470 since the conduction of a trial. There are several ways of how to implement this as a covariable. 470 since the conduction of a trial. There are several ways of how to implement this as a covariable.
471 We decided to take the difference of the voungest antibiotics in both treatment arms, as we
- 471 We decided to take the difference of the youngest antibiotics in both treatment arms, as we 472 axpected that novel antibiotics are more likely to be tested in the treatment arm with lower 472 expected that novel antibiotics are more likely to be tested in the treatment arm with lower
473 antibiotics. 473 antibiotics.
474 For our mu
- 474 For our multi-model inference, we excluded the variables considering whether a study was
475 conducted in an ICU, and whether additional drugs were administered as we could not cont
- 475 conducted in an ICU, and whether additional drugs were administered as we could not confidently 476 obtain information regarding those variables for more than half of the studies. Due to a high
- 476 obtain information regarding those variables for more than half of the studies. Due to a high
477 correlation between the administration of antibiotics common to the treatment arms and sam
- 477 correlation between the administration of antibiotics common to the treatment arms and same
478 dosage (acquisition of resistance: 0.95, *de novo* emergence of resistance: 0.91) we excluded t 478 dosage (acquisition of resistance: 0.95, *de novo* emergence of resistance: 0.91) we excluded the variable same dosage from the meta-regressions.
- 480 Our multi model inference showed that for acquisition of resistance the most important covariable 481 to include in a meta-regression model to explain some of the observed heterogeneity was
- 481 to include in a meta-regression model to explain some of the observed heterogeneity was
482 vhether antibiotics common to the treatments were used or not (table S7). This is in line w
- 482 whether antibiotics common to the treatments were used or not (table S7). This is in line with our
- 483 sub-group analysis performed (main text figure 3B). By including the information whether at least 484 one antibiotic was common to both treatment arms in a meta-regression, we could find a
- 484 one antibiotic was common to both treatment arms in a meta-regression, we could find a
485 decrease in the estimated heterogeneity (l^2 =59, no-meta-regression: l^2 =77), but neverthe 485 decrease in the estimated heterogeneity (l^2 =59, no-meta-regression: l^2 =77), but nevertheless the
- 486 heterogeneity remains substantial (table S8). Furthermore, we could confirm once more that a
487 bower number of antibiotics performs better, if in the treatment arms no common antibiotics are
- 487 lower number of antibiotics performs better, if in the treatment arms no common antibiotics are
488 used (tables S7, S8). For *de novo* emergence of resistance, the multi model inference did not 488 used (tables S7, S8). For *de novo* emergence of resistance, the multi model inference did not
- 489 show any significant covariables (table S9).
490 Overall, this does not necessarily mean that
- 490 Overall, this does not necessarily mean that any of the covariables are not impacting the outcome
491 of resistance development significantly, but since most studies were underpowered (main text
- 491 of resistance development significantly, but since most studies were underpowered (main text
492 figure 2 B) there is the possibility that we are missing important signals. figure 2 B) there is the possibility that we are missing important signals.
- 493
- 494 **Table S7.** Overview of the model averaged coefficients obtained by the multi-model inference for 495 the main outcome acquisition of resistance. Significant model estimates are displayed in a bold
- the main outcome acquisition of resistance. Significant model estimates are displayed in a bold
- 496 font.

- 498 **Table S8.** Model output for a meta-regression for acquisition of resistance including as a
- 499 covariable, whether at least one antibiotic was in common in the treatment arms. Significant 4500 model estimates are displayed in a bold font.
- model estimates are displayed in a bold font.

501

502 **Table S9.** Overview of the model averaged coefficients obtained by the multi-model inference for
503 the main outcome *de novo* emergence of resistance. the main outcome *de novo* emergence of resistance.

Model-averaged coefficients (full- average)	Estimated	Standard error	z value	Pr(> z)
Intercept	2.22	2.42	0.90	0.37
Length of follow-up	0.99	1.01	0.73	0.46
Treatment length	1.00	1.01	0.41	0.68
2 vs. 3 antibiotics	1.29	2.51	0.28	0.78
Antibiotics in common: yes	0.32	2.66	1.16	0.25
Comorbidity: yes	1.40	2.03	0.47	0.64
Gram positive and negative bacteria	1.45	2.23	0.47	0.64
Gram positive bacteria	1.16	1.98	0.21	0.83
Year difference of youngest antibiotics	0.99	1.02	0.30	0.72

504

505

506 **8. Statistical power**

507 *8.1. Adequate treatment arm size*

508 Resistance development is a rare event and therefore differences in resistance development are
509 difficult to detect in small population sizes. To illustrate this, we calculated how much participants 509 difficult to detect in small population sizes. To illustrate this, we calculated how much participants

 510 would have needed to be included per treatment harm in order to detect whether a higher number 511 of antibiotics would half the odds of occurrence of resistance and compared it to the actual

- of antibiotics would half the odds of occurrence of resistance and compared it to the actual
- 512 number of participants (figure S6). For the calculations we assumed a power of 80% and used for
- 513 each trial the upper confidence interval for the probability of resistance development in the
514 treatment arm with the lower number of antibiotics. The confidence interval was determined
- 514 treatment arm with the lower number of antibiotics. The confidence interval was determined with

Bayesian inference.

516

517

518 **Fig. S6.** The calculated adequate treatment arm size for each study assuming to detect an odds 519 ratio of 0.5 with 80% power in comparison to the actual treatment arm sizes. The power 519 ratio of 0.5 with 80% power in comparison to the actual treatment arm sizes. The power
520 calculations were performed using the upper confidence interval for the binomial probabi 520 calculations were performed using the upper confidence interval for the binomial probability of the
521 treatment arm with less antibiotics. treatment arm with less antibiotics.

522

523

524 *8.2. Trial sequential analysis*

525 It is expected that pooling data from several RCTs results in a high level of evidence.
526 Nevertheless, meta-analysis might lead to inconclusive results or even misleading on 526 Nevertheless, meta-analysis might lead to inconclusive results or even misleading ones as meta-
527 analyses can also suffer from low statistical power (69). Therefore, we performed for our two 527 analyses can also suffer from low statistical power (69). Therefore, we performed for our two
528 main outcomes a trial sequential analysis (TSA), using the TSA tool version 0.9.5.10 Beta 528 main outcomes a trial sequential analysis (TSA), using the TSA tool version 0.9.5.10 Beta
529 (Copenhagen: The Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2016 529 (Copenhagen: The Copenhagen Trial Unit, Centre for Clinical Intervention Research, 2016) to
530 assess how strong and sufficient the evidence of our overall analyses is. For both outcomes th 530 assess how strong and sufficient the evidence of our overall analyses is. For both outcomes the 531 TSA supports that the existing evidence on resistance development is not sufficient and 531 TSA supports that the existing evidence on resistance development is not sufficient and
532 conclusive, as the trial sequential monitoring boundary is not crossed by the Z-curve in a 532 conclusive, as the trial sequential monitoring boundary is not crossed by the Z-curve in any of the 533 cases, nor is the required sample size reached (figure S7). For the TSA calculations we used 533 cases, nor is the required sample size reached (figure S7). For the TSA calculations we used
534 resistance incidence rate per treatment arm, which we calculated by averaging the incidence 534 resistance incidence rate per treatment arm, which we calculated by averaging the incidence 535 rates of all included studies (per outcome). For interested readers technical details of the TSA 536 can be found elsewhere (69, 70). The TSA analysis is an additional analysis, which was not predefined in our study protocol. predefined in our study protocol.

540 **Fig. S7.** TSA output using 80% power, and 5% significance to detect a relative odds reduction of 541 50%: A) acquisition of resistance. B) *de novo* emergence of resistance. No sufficient evidence on 541 50%: A) acquisition of resistance. B) *de novo* emergence of resistance. No sufficient evidence on 542 development of resistance is supported, since the \overline{Z} -curves do not cross the monitoring nor the futility boundaries, and the required sample size is not reached. futility boundaries, and the required sample size is not reached.

545 **9. Secondary Outcomes**

 546 In the evaluation of an optimal antibiotic treatment strategy many factors play a role besides the 547 potential spread of antibiotic resistance and therewith the future potential to treat infections 547 potential spread of antibiotic resistance and therewith the future potential to treat infections
548 successfully. One important factor, which is naturally the focus of clinical research, is the 548 successfully. One important factor, which is naturally the focus of clinical research, is the 549 vellbeing of the patient receiving antibiotic treatment. Antibiotic combination therapy is of 549 wellbeing of the patient receiving antibiotic treatment. Antibiotic combination therapy is often
550 associated with a higher medical burden for the treated patient, e.g. through a higher risk of 550 associated with a higher medical burden for the treated patient, e.g. through a higher risk of 551 toxicity (71). To present are more comprehensive evaluation of antibiotic combination therap 551 toxicity (71). To present are more comprehensive evaluation of antibiotic combination therapy, we
552 systematically summarised the following outcomes as an indication for the wellbeing of the 552 systematically summarised the following outcomes as an indication for the wellbeing of the
553 treated patient: (i) All-cause mortality, (ii) mortality attributable to infection, (iii) treatment fai 553 treated patient: (i) All-cause mortality, (ii) mortality attributable to infection, (iii) treatment failure,
554 (iv) treatment failure due to a change of resistance against the study drugs, and (v) proportion or 554 (iv) treatment failure due to a change of resistance against the study drugs, and (v) proportion of 555 patients with alterations to the treatment due to adverse events. Additionally, we collected data or 555 patients with alterations to the treatment due to adverse events. Additionally, we collected data on
556 acquisition, and *de novo* emergence of resistance against non-administered antibiotics to further 556 acquisition, and *de novo* emergence of resistance against non-administered antibiotics to further 557 assess the risk of resistance spread, which might affect future treatment success. Overall, we did
558 not find any indication of a difference for any of these evaluation metrics of combining a higher 558 not find any indication of a difference for any of these evaluation metrics of combining a higher number of antibiotics in comparison to less as presented below.

560 *9.1. All-cause mortality* 561 We extracted the number of patients that died in a study as reported. We did not identify a
562 mortality difference of using a higher number of antibiotics opposed to less (figure S8). One 562 mortality difference of using a higher number of antibiotics opposed to less (figure S8). One must 563 consider that the estimated pooled OR 0.98 (95% Cl 0.79 – 1.21) was based on several RCTs 563 consider that the estimated pooled OR 0.98 (95% CI 0.79 – 1.21) was based on several RCTs 564 with different sources of potential heterogeneity, which we did not account for in our statistical 565 analysis of secondary outcomes. Nevertheless, the heterogeneity in our random effects model for 566 all-cause mortality could be classified as unimportant $(l^2=11\%)$. In previously conducted meta-566 all-cause mortality could be classified as unimportant $(1^2=11\%)$. In previously conducted meta-567 analyses evaluating antibiotic combination therapy mortality was often the main outcome, but the 568 inclusion criteria were less broad, constrained to specific diseases, pathogens, or particular 568 inclusion criteria were less broad, constrained to specific diseases, pathogens, or particular antibiotic combinations. The results of those meta-analyses do not easily generalize to one 570 overall trend, but rather highlight that sub-analyses accounting for specific infections and
571 antibiotic comparisons might be important as we found for our main outcomes of resistan 571 antibiotic comparisons might be important as we found for our main outcomes of resistance
572 development (72-74). Nevertheless, we found in line with most previous meta-analyses no c 572 development (72-74). Nevertheless, we found in line with most previous meta-analyses no clear
573 harm or benefit of combining a higher number of antibiotics or less with respect to all-cause 573 harm or benefit of combining a higher number of antibiotics or less with respect to all-cause
574 mortality. mortality.

578
579

579 *9.2. Mortality attributable to infection*

580 Besides all cause-mortality we also extracted the number of deaths that the respective study
581 authors attributed to the infection treated. As for all-cause mortality our estimate for mortality
582 attributable to in 581 authors attributed to the infection treated. As for all-cause mortality our estimate for mortality 582 attributable to infection indicated no difference between treating with a higher number of antibiotics in comparison to less (pooled OR 1.05, 95% Cl 0.64 – 1.71; figure S9), and the heterogeneity could also be classif antibiotics in comparison to less (pooled OR 1.05, 95% CI 0.64 – 1.71; figure S9), and the model 584 heterogeneity could also be classified as unimportant $(I^2=12\%)$.

⁵⁷⁷ **Fig. S8.** Forest plot of all-cause mortality.

587 **Fig. S9.** Forest plot of mortality attributable to infection.

588

589 *9.3. Treatment failure*

590 We extracted the number of treatment failures in each treatment arm if treatment failure was
591 explicitly defined or classified by the study authors. As the selection of studies for this meta-591 explicitly defined or classified by the study authors. As the selection of studies for this meta-592 analysis was not restricted to one specific pathogen, or condition requiring antibiotic treatment,
593 we expected a variety of different reasons for the employment of antibiotics. Out of practicality 593 we expected a variety of different reasons for the employment of antibiotics. Out of practicality
594 and to account for the different conditions treated, we decided not to pre-define our own criteria 594 and to account for the different conditions treated, we decided not to pre-define our own criteria
595 for treatment failure for each condition, but rather use the study's authors interpretation of 595 for treatment failure for each condition, but rather use the study's authors interpretation of 596 treatment failure (table S10). 596 treatment failure (table S10).
597 Our estimate gave no indicati

597 Our estimate gave no indication for a difference in treatment failure when treating with a higher
598 number of antibiotics in comparison with a lower number of antibiotics if treatment failure was 598 number of antibiotics in comparison with a lower number of antibiotics if treatment failure was
599 considered (pooled OR 0.98, 95% CI 0.66 – 1.47; figure S10). However, we observed a

599 considered (pooled OR 0.98, 95% CI 0.66 – 1.47; figure S10). However, we observed a
600 substantial amount of heterogeneity in our model (l^2 =74%), which might indicate that for

600 substantial amount of heterogeneity in our model (l^2 =74%), which might indicate that for some

601 bacterial conditions or some antibiotic combinations there might be a difference.

603 **Table S10.** Overview of different treatment failure definitions.

Study	Definition of treatment failure given by the study authors
Cometta et al. (1994)(9)	Lack of improvement of primary infection, development of a sepsis syndrome or septic shock during treatment, superinfection
Durante-Mangoni et al. (2013)(14)	No improvement of clinical conditions by day 21 or worsening of the condition at any time, given persistently positive Acinetobacter baumannii cultures
Gerecht et al. (1989)(16)	Continued presence of infecting organism(s) in bile cultures, with persistent indications of cholangitis, or superinfection, or the presence of new infecting organism(s) during or at the end of antibiotic treatment, with indications of cholangitis, or emergence of an infecting organism(s) resistant to gentamicin or mezlocillin during treatment, with indications of cholangitis, or emergence of an infecting organism(s) resistant to gentamicin or mezlocillin during treatment, with indications of cholangitis, or relapse, or recurrence of indications of cholangitis, with the original infecting organism(s) present in cultures of bile or blood within eight weeks after treatment, or death due to uncontrolled infection.
Haase et al. (1984)(18)	The persisting presence of the pretherapy infecting organism, with or without pyuria, during treatment.
Hartbarth et al. (2015)(19)	No improvement or worsening in the clinical condition, or a change of the assigned therapy at any time, or death.
Jacobs et al. (1993)(24)	No apparent response to therapy and no definitive identification of an alternative etiology that would explain this lack of response.
Markowitz et al. (1992)(27)	Persistence of septic pulmonary emboli, persistence of positive blood or deep tissue cultures, or relapse after the end of presumably adequate treatment.
May et al. (1997)(29)	Treatment failure was defined as all other situations than success, whereas the primary determinants of success were as follows: patient living, either not fever or a reduction of ≥ 1 °C in initial body temperature, and a blood culture negative for M. avium
Parry et al. (2007)(35)	Continuing fever with at least one other typhoid-related symptom for more than seven days after the start of treatment, or a required change in therapy due to the development of severe complications during treatment (severe gastrointestinal bleeding, intestinal perforation, visible jaundice, myocarditis, pneumonia, renal failure, shock, or an altered conscious level)
Paul et al. (2015)(36)	Treatment failure at seven days was defined as a composition of death, persistence of fever, persistence of hypotension, non-improving Sequential Organ Failure Assessment score, or persistent bacteraemia on day seven.
Pogue et al. (2021)(37)	Clinical failure was defined by meeting any of the following criteria: death either during therapy or within 7 days after; receipt of rescue therapy for the trial pathogen within 7 days after treatment, exclusion from the trial due to an adverse event considered related to trial treatment; bacteremia more than 5 days after the begin of therapy for patients with blood stream infections; or failure to improve or worsening of oxygenation by the end of trial treatment in patients with pneumonia.
Pujol et al. (2021)(38)	No clinical improvement after 3 days of therapy, persistent MRSA bacteraemia at day 7 or later, early discontinuation of therapy due to adverse events or based on clinical judgment, recurrent MRSA bacteraemia before or at test of cure, missing blood cultures at test of cure, and/or death due to any cause before test of cure.
Rubinstein et al. (1995)(39)	Use of a new antibiotic due to a worsening in clinical condition, isolation of resistant organism, or

606 **Fig. S10.** Forest plot of treatment failure.

607

608 *9.4. Treatment failure due to a change of resistance against the study drugs*

 609 We could only extract information for treatment failure due to a change of resistance against the 610 study drugs from three out of the 42 studies. As one of the studies had zero-events in both 610 study drugs from three out of the 42 studies. As one of the studies had zero-events in both
611 treatment arms our statistical summary estimate was only based on two studies and should 611 treatment arms our statistical summary estimate was only based on two studies and should therefore be interpreted with caution. Nevertheless, as for treatment failure we did not identiting 612 therefore be interpreted with caution. Nevertheless, as for treatment failure we did not identify a difference of using a higher number of antibiotics in comparison to less when considering 613 difference of using a higher number of antibiotics in comparison to less when considering 614 treatment failure due to a change of resistance against the study drugs (pooled LOR 0.61) 614 treatment failure due to a change of resistance against the study drugs (pooled LOR 0.61, 95% 615 Cl 0.29 – 1.28; l^2 =1%; figure S11). 615 CI 0.29 – 1.28; l^2 =1%; figure S11). 616

618 **Fig. S11.** Forest plot of treatment failure due to a change of resistance against the study drugs.

619

620 *9.5. Alterations of the prescribed treatment due to adverse events*

 621 To get an indication how well the treatments were tolerated by the patients we extracted data on alterations of the prescribed treatment due to adverse events. We did identify benefit of using a 622 alterations of the prescribed treatment due to adverse events. We did identify benefit of using a
623 lower number of antibiotics in comparison to a higher one. The heterogeneity in the random 623 lower number of antibiotics in comparison to a higher one. The heterogeneity in the random
624 effects model could be classified as unimportant (pooled OR 1.61, 95% CI 1.12 – 2.31; $l^2=5^{\circ}$ 624 effects model could be classified as unimportant (pooled OR 1.61, 95% CI 1.12 – 2.31; l^2 =5%; 625 figure S12).

628 **Fig. S12.** Forest plot of alterations of the prescribed treatment due to adverse events.

629

 9.6. Acquisition of resistance against non-administered antibiotics 631 There are several ways of how bacteria may get resistant against antibiotics, one of them is the through acquiring antibiotic resistance plasmids. Clinically relevant plasmids often confer 632 through acquiring antibiotic resistance plasmids. Clinically relevant plasmids often confer 633 resistance against multiple antibiotics (59-61). Therefore, one might expect if a patient is t resistance against multiple antibiotics (59-61). Therefore, one might expect if a patient is treated 634 with a higher number of antibiotics the chances increase to acquire multidrug resistant plasmids 635 that confer resistances to antibiotics that are not part of the current treatment. In addition, one that confer resistances to antibiotics that are not part of the current treatment. In addition, one 636 could expect, that the chances for cross resistances increase, i.e., the obtained resistance could expect, that the chances for cross resistances increase, i.e., the obtained resistance 637 confers resistances to several antibiotics. if a higher number of antibiotics is administered. confers resistances to several antibiotics, if a higher number of antibiotics is administered. To 638 check this reasoning, we extracted the data for acquisition, and *de novo* emergence of resista check this reasoning, we extracted the data for acquisition, and *de novo* emergence of resistance against non-administered antibiotics.
 640 For seven studies we extracted the d

 640 For seven studies we extracted the data for acquisition of resistance against non-administered 641 antibiotics, but we could only use three of them for our statistical analyses as the other studies

- 641 antibiotics, but we could only use three of them for our statistical analyses as the other studies 642 had zero events in both treatment arms. As the statistical analysis was only based on three
- 642 had zero events in both treatment arms. As the statistical analysis was only based on three 643 studies and the model showed moderate to substantial heterogeneity (l^2 =60%) our estimate 643 studies and the model showed moderate to substantial heterogeneity (l^2 =60%) our estimate might
- 644 not be sufficient to confidently give an indication. The pooled LOR of our random effects model
- 645 suggested no difference in using a higher number of antibiotics in comparison to less to reduce 646 acquisition of resistance against non-administered drugs (OR 0.39, 95% CI 0.02 8.48; figure
- 646 acquisition of resistance against non-administered drugs (OR 0.39, 95% CI 0.02 8.48; figure 647 S13).
- 648

Antibiotics More Study / Less OR (95% CI) OR (95% CI) subgroup (n/N) (n/N) Dekker 1987¹¹ 0·10 [0·00, 1·86] 4 / 28 0 / 28 Paul 2015³⁶ 0·29 [0·01, 7·10] 1 / 117 0 / 135 Smith 1999⁴² 5·69 [0·28, 114·52] 0 / 30 3 / 40 Gibson 1989¹⁷ 0 / 8 $0/13$ Haase 1984¹⁸ 0 / 21 0 / 21 Markowitz 1992²⁷ 0 / 58 0 / 43 Walsh 1993⁴⁴ 0 / 45 0 / 49 Total (95% CI) 0·39 [0·02, 8·48] Heterogeneity: τ^2 =3.65; I^2 =60% **Favors a higher number of antibiotics Favors fewer antibiotics**Г Τ Т \mathbf{I} 0 0·02 0·14 1 7·39 54·6 403·43

649

- 650 **Fig. S13.** Forest plot of acquisition of resistance against non-administered antibiotics.
- 651

652 *9.7.* **De novo** *emergence of resistance against non-administered antibiotics*

653 As for the main outcomes we distinguished between acquisition and *de novo* emergence of resistance. According to our definition (main text: Methods), *de novo* emergence of resistance is 655 a subset of acquisition of resistance. For acquisition of resistance against non-administered 656 antibiotics we obtained three studies eligible for the statistical analysis, for de novo emergen 656 antibiotics we obtained three studies eligible for the statistical analysis, for *de novo* emergence 657 only two. Therefore, the estimates need to be taken with consideration. As for acquisition of 658 resistance against non-administered antibiotics there was no indication for a difference of us 658 resistance against non-administered antibiotics there was no indication for a difference of using a
659 higher or a lower number of antibiotics (pooled OR 1.91, 95% CI 0.09 – 39.69; l^2 =33%; figure 659 higher or a lower number of antibiotics (pooled OR 1.91, 95% CI 0.09 - 39.69; l^2 =33%; figure 660 S14).

- 663 **Fig. S14.** Forest plot of *de novo* emergence of resistance against non-administered antibiotics.
- 664

665 **10. List of contacted authors and reasoning for exclusion of studies included in previous** 666 **meta-analyses**

667 An overview of authors, that were contacted for clarification of study data, is shown in table S11.
668 In our meta-analysis we excluded some studies that were included in previous meta-analyses 668 In our meta-analysis we excluded some studies that were included in previous meta-analyses 669 focusing on resistance development (72, 75). An overview of those studies and an exclusion 669 focusing on resistance development (72, 75). An overview of those studies and an exclusion reason is given in table S12.

672 **Table S11.** List of studies for which study authors or institutions were contacted. An indication is given whether clarifying information was obtained.

Study	Person/Institution contacted	Information sufficient for paper inclusion obtained (yes/no)
Bazolli 1998(76)	Franco Bazolli	no
Benson 2000(77)	Constance Benson	no

675 **Table S12.** Table of studies, which were included in previous meta-analyses, but excluded in our 676 study. The reason for exclusion is indicated. *In our protocol we stated, that we would include 676 study. The reason for exclusion is indicated. ^{*}In our protocol we stated, that we would include articles in Russian language. However, since VNK, the only Russian speaking author, did not screen all the papers from o screen all the papers from our systematic search for inclusion, we excluded studies in Russian

language.

681 **11. Search strategy**

682 *11.1. PubMed*

- 683 ((((((((((("Bacterial Infections/Drug Therapy"[mesh]) OR "Bacterial Infections/drug effects"[Mesh])
684 OR "Bacteria/drug effects"[Mesh]) OR "Bacteria/Drug Therapy"[mesh]) OR (((infection[tiab] OR
- 684 OR "Bacteria/drug effects"[Mesh]) OR "Bacteria/Drug Therapy"[mesh]) OR (((infection[tiab] OR
685 infections[tiab]) AND bacteria*)))) AND (((((((((((((((("beta-Lactams/Administration and
- 685 infections[tiab]) AND bacteria*)))) AND (((((((((((((((((("beta-Lactams/Administration and 686 Dosage"[mesh] OR "beta-Lactams/Therapeutic Use"[mesh]) OR
- 686 Dosage"[mesh] OR "beta- Lactams/Therapeutic Use"[mesh])) OR
- 687 ("Aminoglycosides/Administration and Dosage"[mesh] OR "Aminoglycosides/Therapeutic
688 Use"[mesh])) OR ("Chloramphenicol/Administration and Dosage"[mesh] OR
- 688 Use"[mesh])) OR ("Chloramphenicol/Administration and Dosage"[mesh] OR
- 689 "Chloramphenicol/Therapeutic Use"[mesh])) OR ("Glycopeptides/Administration and
- 690 Dosage"[mesh] OR "Glycopeptides/Therapeutic Use"[mesh])) OR ("Rifamycins/Administration
691 and Dosage"[mesh] OR "Rifamycins/Therapeutic Use"[mesh])) OR
- 691 and Dosage"[mesh] OR "Rifamycins/Therapeutic Use"[mesh])) OR
- 692 ("Streptogramins/Administration and Dosage"[mesh] OR "Streptogramins/Therapeutic
693 Use"[mesh])) OR ("Sulfonamides/Administration and Dosage"[mesh] OR
- 693 Use"[mesh])) OR ("Sulfonamides/Administration and Dosage"[mesh] OR
- 694 "Sulfonamides/Therapeutic Use"[mesh])) OR ("Tetracyclines/Administration and Dosage"[mesh]
- 695 OR "Tetracyclines/Therapeutic Use"[mesh])) OR ("Macrolides/Administration and Dosage"[mesh]
696 OR "Macrolides/Therapeutic Use"[mesh])) OR ("Oxazolidinones/Administration and
- 696 OR "Macrolides/Therapeutic Use"[mesh])) OR ("Oxazolidinones/Administration and
697 Dosage"[mesh] OR "Oxazolidinones/Therapeutic Use"[mesh])) OR
- 697 Dosage"[mesh] OR "Oxazolidinones/Therapeutic Use"[mesh])) OR
- 698 ("QUINOLONES/Administration and Dosage"[mesh] OR "QUINOLONES/Therapeutic
- 699 Use"[mesh])) OR ("Lipopeptides/Administration and Dosage"[mesh] OR
- 700 "Lipopeptides/Therapeutic Use"[mesh])) OR ("Anti-Bacterial Agents/Administration and
701 Dosage"[mesh:noexp]))) OR "Anti-Bacterial Agents/Therapeutic Use"[mesh:noexp]) OR
- 701 Dosage"[mesh:noexp]))) OR "Anti-Bacterial Agents/Therapeutic Use"[mesh:noexp]) OR "Anti-
- 702 Bacterial Agents/Therapy"[mesh:noexp]) OR antibiotic*[tiab])) AND (((((((("Drug Therapy,
- 703 Combination"[mesh:noexp]) OR "drug combinations"[mesh:noexp]) OR "trimethoprim,
- 704 sulfamethoxazole drug combination"[mesh:noexp]) OR "Drug Synergism"[mesh:noexp]))) OR
- (combination[tiab] AND (therapy[tiab] OR therapies[tiab]))) OR combinationtherap*[tiab])) AND
- 706 ((("Drug Resistance, Bacterial"[Mesh]) OR "Drug Resistance, Microbial"[Mesh:noexp]) OR
- 707 resistan*[tiab]))) NOT (((("Complementary Therapies"[Mesh]) OR "Plant Extracts"[Mesh]) OR
- bismuth[tiab]) OR "Bismuth"[Mesh]))) AND "Controlled Clinical Trial"[Publication Type]

709 *11.2. CENTRAL*

- #1 MeSH descriptor: [Bacterial Infections] explode all trees and with qualifier(s): [drug therapy -
- 711 DT] 712 #2 MeSH descriptor: [Bacteria] explode all trees and with qualifier(s): [drug effects -
713 #3 ((infection):ti.ab.kw OR (infections):ti.ab.kw) AND bacteria*
- 713 #3 ((infection):ti,ab,kw OR (infections):ti,ab,kw) AND bacteria*
- 714 $#4$ MeSH descriptor: [beta-Lactams] explode all trees and with qualifier(s): [administration & 715 dosage AD,
- 715 dosage AD,
716 therapeutic us
- 716 therapeutic use TU]
717 #5 MeSH descriptor: |
- 717 #5 MeSH descriptor: [Chloramphenicol] explode all trees and with qualifier(s): [administration & 718 dosage AD, therapeutic use TU] 718 dosage - AD, therapeutic use - TU]
- 719 #6 MeSH descriptor: [Aminoglycosides] explode all trees and with qualifier(s): [administration & 720 dosage - AD, therapeutic use - TU]
- 721 #7 MeSH descriptor: [Glycopeptides] explode all trees and with qualifier(s): [administration &
- 722 dosage AD, therapeutic use TU]
- 723 #8 MeSH descriptor: [Rifamycins] explode all trees and with qualifier(s): [administration & dosage 724 - AD, therapeutic use - TU]
725 #9 MeSH descriptor: [Strep
- 725 #9 MeSH descriptor: [Streptogramins] explode all trees and with qualifier(s): [administration & 726 dosage AD, therapeutic use TU]
- dosage AD, therapeutic use TU]
- 727 #10 MeSH descriptor: [Sulfonamides] explode all trees and with qualifier(s): [administration & 728 dosage AD, therapeutic use TU] dosage - AD, therapeutic use - TU] #11 MeSH descriptor: [Macrolides] explode all trees and with qualifier(s): [administration & dosage - AD, therapeutic use - TU] #12 MeSH descriptor: [Tetracyclines] explode all trees and with qualifier(s): [administration & dosage - AD, therapeutic use - TU] #13 MeSH descriptor: [Oxazolidinones] explode all trees and with qualifier(s): [administration & 734 dosage - AD, therapeutic use - TU]
735 #14 MeSH descriptor: [Quinolones] #14 MeSH descriptor: [Quinolones] explode all trees and with qualifier(s): [administration & 736 dosage - AD, therapeutic use - TU]
737 #15 MeSH descriptor: [Lipopeptides #15 MeSH descriptor: [Lipopeptides] explode all trees and with qualifier(s): [administration & dosage - AD, therapeutic use - TU] #16 MeSH descriptor: [Anti-Bacterial Agents] this term only and with qualifier(s): [administration & dosage - AD, therapeutic use - TU] #17 (antibiotic*):ti,ab,kw 742 #18 MeSH descriptor: [Drug Therapy, Combination] this term only
743 #19 MeSH descriptor: [Drug Combinations] this term only #19 MeSH descriptor: [Drug Combinations] this term only #20 MeSH descriptor: [Trimethoprim, Sulfamethoxazole Drug Combination] this term only #21 MeSH descriptor: [Drug Synergism] this term only 746 #22 ((combination):ti,kw,ab) NEAR/3 ((therapy):ti,kw,ab OR (therapies):ti,ab,kw)
747 #23 (combinationtherap*):ti.ab.kw #23 (combinationtherap*):ti,ab,kw 48 #24 MeSH descriptor: [Drug Resistance, Bacterial] explode all trees
749 #25 MeSH descriptor: [Drug Resistance, Microbial] this term only 749 #25 MeSH descriptor: [Drug Resistance, Microbial] this term only
750 #26 (resistan*):ti.ab.kw #26 (resistan*):ti,ab,kw 751 #27 MeSH descriptor: [Complementary Therapies] explode all trees
752 #28 MeSH descriptor: [Plant Extracts] explode all trees #28 MeSH descriptor: [Plant Extracts] explode all trees #29 (bismuth):ti,ab,kw #30 MeSH descriptor: [Bismuth] explode all trees
 755 #31 {OR # 1-# 3} #31 {OR # 1-# 3} #32 {OR # 4-#17} #33 {OR #18-#23} #34 {OR #24-#26} #35 {AND #31-#34} #36 {OR # 27-#30} #37 #35 NOT #36 *11.3. EMBASE* #26. #24 AND #25 #25. 'controlled clinical trial'/exp #24. #23 NOT #22 #23. #18 AND #19 AND #20 AND #21 #22. #14 OR #15 OR #16 OR #17 #21. #12 OR #13 #20. #7 OR #8 OR #9 OR #10 OR #11 #19. #5 OR #6 #18. #1 OR #2 OR #3 OR #4 #17. 'herbal medicine'/exp 773 #16. 'alternative medicine'/exp
774 #15. 'bismuth'/exp 774 #15. 'bismuth'/exp
775 #14. bismuth:ti,ab, #14. bismuth:ti,ab,kw #13. resistan*:ti,ab,kw #12. 'antibiotic sensitivity'/exp #11. (combination NEAR/3 (therapy OR therapies)):ti,ab,kw #10. combinationtherap*:ti,ab,kw #9. 'antibiotic agent'/exp/dd cb 781 #8. 'drug potentiation'/de
782 #7. 'combination drug the
- #7. 'combination drug therapy'/de
- 783 #6. 'antibiotic*':ti,ab,kw
784 #5. 'antibiotic agent'/exp
- 784 #5. 'antibiotic agent'/exp
- 785 #4. (infection:ti,ab,kw OR infections:ti,ab,kw) AND bacteria*
786 #3. 'bacterial infection'/exp
- 786 #3. 'bacterial infection'/exp
787 #2. 'bacterium'/exp
- 787 #2. 'bacterium'/exp
- #1. 'prokaryotes by outer appearance'/exp

789 790 *11.4. Screening of eligible trials and previous meta-analyses*

791
792 792 In addition to the systematic database search, we also screened the references of eligible studies
793 and the trials included in two previous meta-analyses (72, 75). With the database search we 793 and the trials included in two previous meta-analyses (72, 75). With the database search we 794 identified 41 studies. While screening the references of those 41 studies we identified one
795 additional study (45), which meets our inclusion criteria. This additional study was not iden 795 additional study (45), which meets our inclusion criteria. This additional study was not identified in 796
796 our search strategy as neither the abstract nor database specific identifiers gave any indication 796 our search strategy as neither the abstract nor database specific identifiers gave any indication
797 that resistance was measured in this study. The screening of the trials included in two previous 797 that resistance was measured in this study. The screening of the trials included in two previous
798 analyses did not result in inclusion of further studies (table S12). analyses did not result in inclusion of further studies (table S12).

SI References

 1. Kerantzas Christopher A, Jacobs William R, Rubin Eric J, Collier RJ. Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application. mBio.8(2):e01586-16.

 2. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10 Suppl 2):S231-79.

 3. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.

 4. Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. The Lancet Infectious Diseases. 2018;18(4):391-400.

 5. Kaye Keith S, Marchaim D, Thamlikitkul V, Carmeli Y, Chiu C-H, Daikos G, et al. Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms. NEJM Evidence. 2022;2(1):EVIDoa2200131.

 6. Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, et al. Role of vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in leukemic patients. Antimicrobial agents and chemotherapy. 1979;15(3):455-60.

 7. Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-sulfamethoxazole, or placebo. Reviews of infectious diseases. 1982;4(2):540-5.

 8. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS (london, england). 1997;11(3):311-7.

 9. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrobial agents and chemotherapy. 1994;38(6):1309-13.

 10. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open- label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet (london, england). 2015;385(9979):1738-47.

 11. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Annals of internal medicine. 1987;106(1):7-11.

 12. Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, et al. Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs. Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms. Clinical infectious diseases : an official publication of the

Infectious Diseases Society of America. 2019.

 13. Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, et al. A 846 randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. Journal of Infectious Diseases. 1997;176(5):1225-32.

 14. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clinical infectious diseases. 2013;57(3):349-58.

 15. Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M. Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. European journal of clinical microbiology & infectious diseases. 1999;18(1):16-22.

 16. Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE, et al. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Archives of internal medicine. 1989;149(6):1279-84.

 17. Gibson J, Date L, Joshua DE, Young GA, Wilson A, Benn R, et al. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin. Australian and new zealand journal of medicine. 1989;19(5):417-25.

 18. Haase DA, Harding GK, Thomson MJ, Kennedy JK, Urias BA, Ronald AR. Comparative trial of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized, acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal microflora. Antimicrobial agents and chemotherapy. 1984;26(4):481-4.

 19. Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, et al. Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection. Journal of antimicrobial 873 chemotherapy. 2015;70(1):264-72.

 20. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis. Lancet (london, england). 1987;1(8527):235-7.

 21. Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparative study of ceftriaxone monotherapy versus a combination regimen of cefuroxime plus gentamicin 879 for treatment of serious bacterial infections: the efficacy, safety and effect on fecal flora. Chemotherapy. 1988;34 Suppl 1:21-9.

 22. Hultén K, Jaup B, Stenquist B, Engstrand L. Combination treatment with ranitidine is highly efficient against Helicobacter pylori despite negative impact of macrolide resistance. Helicobacter. 1997;2(4):188-93.

 23. Iravani A, Richard GA, Baer H, Fennell R. Comparative efficacy and safety of nalidixic acid versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract

infections in college-age women. Antimicrobial agents and chemotherapy.

1981;19(4):598-604.

24. Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL.

Ceftazidime versus ceftazidime plus tobramycin in febrile neutropenic children.

Infection. 1993;21(4):223-8.

 25. Jo JH, Harkins CP, Schwardt NH, Portillo JA, Zimmerman MD, Carter CL, et al. Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. Sci Transl Med. 2021;13(625):eabd8077. 26. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. South African medical journal. 1994;84(6):325-8. 27. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Annals of internal medicine. 1992;117(5):390-8. 28. Mavromanolakis E, Maraki S, Samonis G, Tselentis Y, Cranidis A. Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections. Journal of chemotherapy (florence, italy). 1997;9(3):203-7. 29. May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clinical infectious diseases. 1997;25(3):621-9. 30. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatric pulmonology. 1988;4(4):201-4. 913 31. Menon R, Roberts FE, Barr KW, Howard H, Lord VL, Hegarty MA, et al.
914 Comparison of a slow-release trimethoprim with co-trimoxazole: efficacy and sele Comparison of a slow-release trimethoprim with co-trimoxazole: efficacy and selection of resistance in the Enterobacteriaceae. Journal of antimicrobial chemotherapy. 1986;18(3):415-20. 32. Miehlke S, Meining A, Lehn N, Höchter W, Weingart J, Simon T, et al. Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection. Digestion. 1998;59(6):646-50. 33. Parras F, Guerrero MC, Bouza E, Blázquez MJ, Moreno S, Menarguez MC, et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 1995;39(1):175-9. 34. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of 926 pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr. 1977;90(1):144-8. 35. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin- azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrobial agents and chemotherapy. 2007;51(3):819-25. 36. Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ (clinical research ed). 2015;350:h2219.

 37. Pogue JM, Rybak MJ, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, et al. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem. Open Forum Infectious Diseases. 2021;8(SUPPL 1):S418-S9. 38. Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin 942 Infect Dis. 2021;72(9):1517-25. 39. Rubinstein E, Lode H, Grassi C, Castelo A, Ward K, Alanko K, et al. Ceftazidime monotherapy vs. Ceftriaxone/tobramycin for serious hospital- acquired gram-negative infections. Clinical Infectious Diseases. 1995;20(5):1217-28. 40. Schaeffer AJ, Flynn S, Jones J. Comparison of cinoxacin and trimethoprim- sulfamethoxazole in the treatment of urinary tract infections. Journal of urology. 1981;125(6):825-7. 41. Schaeffer AJ, Sisney GA. Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora. Journal of urology. 1985;133(4):628-30. 42. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics. 1999;134(4):413-21. 43. Stack WA, Knifton A, Thirlwell D, Cockayne A, Jenkins D, Hawkey CJ, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the 956 eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic
957 ulceration. American journal of gastroenterology. 1998;93(10):1909-13. ulceration. American journal of gastroenterology. 1998;93(10):1909-13. 44. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim- sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrobial agents and chemotherapy. 1993;37(6):1334-42. 45. Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J 965 Med. 1986;80(5):884-90. 46. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. American journal of medicine. 1990;88(1):36-42. 47. Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-971 10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. 972 Alimentary pharmacology & therapeutics. 1997;11(5):943-52. 48. Jackson D, Law M, Stijnen T, Viechtbauer W, White IR. A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio. Stat Med. 2018;37(7):1059-85. 49. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software. 2010;36(3):1 - 48. 50. Günhan BK, Röver C, Friede T. Random-effects meta-analysis of few studies involving rare events. Research Synthesis Methods. 2020;11(1):74-90. 51. Harbord RM, Egger M, Sterne JAC. A modified test for small-study effects in

meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25(20):3443-57.

 52. Mitchison DA, Selkon JB. Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients. Tubercle. 1957;38(2):85-98. 53. Fox W, Wiener A, Mitchison DA, Selkon JB, Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: A national survey, 1955–56. Tubercle. 1957;38(2):71-84. 54. Handel A, Margolis E, Levin BR. Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol. 2009;256(4):655-62. 55. Exner M, Bhattacharya S, Christiansen B, Gebel J, Goroncy-Bermes P, Hartemann P, et al. Antibiotic resistance: What is so special about multidrug-resistant Gram-negative bacteria? GMS Hyg Infect Control. 2017;12:Doc05. 56. Cacace E, Kim V, Varik V, Knopp M, Tietgen M, Brauer-Nikonow A, et al. Systematic analysis of drug combinations against Gram-positive bacteria. Nature Microbiology. 2023;8(11):2196-212. 57. Vrancianu CO, Popa LI, Bleotu C, Chifiriuc MC. Targeting Plasmids to Limit Acquisition and Transmission of Antimicrobial Resistance. Frontiers in Microbiology. 2020;11. 998 58. Goessweiner-Mohr N, Arends K, Keller W, Grohmann E, Tolmasky Marcelo E, Alonso Juan C. Conjugation in Gram-Positive Bacteria. Microbiology Spectrum. Alonso Juan C. Conjugation in Gram-Positive Bacteria. Microbiology Spectrum. 2014;2(4):2.4.19. 59. Cazares A, Moore MP, Hall JPJ, Wright LL, Grimes M, Emond-Rhéault J-G, et al. A megaplasmid family driving dissemination of multidrug resistance in Pseudomonas. Nature Communications. 2020;11(1):1370. 60. Holt KE, Phan MD, Baker S, Duy PT, Nga TVT, Nair S, et al. Emergence of a Globally Dominant IncHI1 Plasmid Type Associated with Multiple Drug Resistant Typhoid. PLOS Neglected Tropical Diseases. 2011;5(7):e1245. 61. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86. 62. Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46(D1):D1074-d82. 63. Ursu O, Holmes J, Bologa CG, Yang JJ, Mathias SL, Stathias V, et al. DrugCentral 2018: an update. Nucleic Acids Research. 2019;47(D1):D963-D70. 64. McCarthy K, Avent M. Oral or intravenous antibiotics? Aust Prescr. 2020;43(2):45-8. 65. Bartoń K. MuMIn: Multi-Model Inference. 2020. 66. Burnham KP, Anderson DR. Model selection and multimodel inference : a practical information-theoretic approach. Second edition. ed. New York, New York: Springer; 2002. 67. Symonds MRE, Moussalli A. A brief guide to model selection, multimodel inference and model averaging in behavioural ecology using Akaike's information criterion. Behavioral Ecology and Sociobiology. 2011;65(1):13-21. 68. Anderson DR. Model Based Inference in the Life Sciences : A Primer on Evidence. 1st ed. 2008. ed. New York, NY: Springer New York; 2008. 69. Kang H. Trial sequential analysis: novel approach for meta-analysis. Anesth Pain Med (Seoul). 2021;16(2):138-50.

 70. Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC medical research methodology. 2017;17(1):1-18. 71. Tamma Pranita D, Cosgrove Sara E, Maragakis Lisa L. Combination Therapy for Treatment of Infections with Gram-Negative Bacteria. Clinical Microbiology Reviews. 2012;25(3):450-70. 72. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database of Systematic Reviews. 2014(1). 73. Ye C, Wang C, Li Z, Li X, Pan J, Liu L, et al. The Effect of Combination Therapy on Mortality and Adverse Events in Patients with Staphylococcus aureus Bacteraemia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Infectious Diseases and Therapy. 2021;10(4):2643-60. 74. Schmid A, Wolfensberger A, Nemeth J, Schreiber PW, Sax H, Kuster SP. Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis. Scientific Reports. 2019;9(1):15290. 75. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of Aminoglycoside and β-Lactam Combination Therapy versus β-Lactam Monotherapy on the Emergence of Antimicrobial Resistance: A Meta-analysis of Randomized, Controlled Trials. Clinical Infectious Diseases. 2005;41(2):149-58. 76. Bazzoli F, Zagari M, Pozzato P, Varoli O, Fossi S, Ricciardiello L, et al. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 1998;12(5):439-45. 77. Benson CA, Williams PL, Cohn DL, Becker S, Hojczyk P, Nevin T, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double- blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. 2000;181(4):1289-97. 78. Bochenek WJ, Peters S, Fraga PD, Wang W, Mack ME, Osato MS, et al. Eradication of Helicobacter pylori by 7-Day Triple-Therapy Regimens Combining Pantoprazole with Clarithromycin, Metronidazole, or Amoxicillin in Patients with Peptic Ulcer Disease: Results of Two Double-Blind, Randomized Studies. Helicobacter. 2003;8(6):626-42. 79. Bosso JA, Black PG. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J. 1988;7(3):171- 6. 80. Bow EJ, Rayner E, Scott BA, Louie TJ. Selective gut decontamination with nalidixic acid or trimethoprim-sulfamethoxazole for infection prophylaxis in neutropenic cancer patients: relationship of efficacy to antimicrobial spectrum and timing of administration. Antimicrob Agents Chemother. 1987;31(4):551-7. 81. Cruciani M, Concia E, Navarra A, Perversi L, Bonetti F, Aricò M, et al. Prophylactic co-trimoxazole versus norfloxacin in neutropenic children — perspective randomized study. Infection. 1989;17(2):65-9. 82. Dalgic N, Karadag CA, Bayraktar B, Sancar M, Kara O, Pelit S, et al. Ertapenem versus standard triple antibiotic therapy for the treatment of perforated appendicitis in

 pediatric patients: a prospective randomized trial. Zeitschrift fur Kinderchirurgie [Surgery in infancy and childhood]. 2014;24(5):410-8. 83. de Pauw B, Williams K, de Neeff J, Bothof T, de Witte T, Holdrinet R, et al. A randomized prospective study of ceftazidime versus ceftazidime plus flucloxacillin in the empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother. 1985;28(6):824-8. 84. de Pauw BE. [Results of several different controlled studies with ceftazidime in the treatment of infections in immunosuppressed patients]. Infection. 1987;15 Suppl 4:S168-72. 85. Dinubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis. 2005;24(7):443-9. 86. CONTROLLED CLINICAL TRIAL OF SHORT-COURSE (6-MONTH) REGIMENS OF CHEMOTHERAPY FOR TREATMENT OF PULMONARY TUBERCULOSIS: EAST AFRICAN/BRITISH MEDICAL RESEARCH COUNCILS. The Lancet. 1972;299(7760):1079-85. 87. Frank E, Liu J, Kinasewitz G, Moran GJ, Oross MP, Olson WH, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther. 2002;24(8):1292-308. 88. Gold R, Overmeyer A, Knie B, Fleming PC, Levison H. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatr Infect Dis. 1985;4(2):172-7. 89. Grossman RF, Beaupre A, LaForge J, Lampron N, Hanna K. A prospective randomised parallel single-blind comparison of oral ciprofloxacin with oral cotrimoxazole in the treatment of respiratory tract infections in patients with chronic obstructive lung disease. Drug Investigation. 1994;8(2):110-7. 90. Grabe M, Forsgren A, Hellsten S. The effectiveness of a short perioperative course with pivampicillin/pivmecillinam in transurethral prostatic resection: clinical results. Scand J Infect Dis. 1986;18(6):567-73. 91. Guerrant RL, Wood SJ, Krongaard L, Reid RA, Hodge RH. Resistance among fecal flora of patients taking sulfamethoxazole-trimethoprim or trimethoprim alone. Antimicrob Agents Chemother. 1981;19(1):33-8. 92. Heyland DK, Dodek P, Muscedere J, Day A, Cook D. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator- associated pneumonia. Crit Care Med. 2008;36(3):737-44. 93. Jackson MA, Kusmiesz H, Shelton S, Prestidge C, Kramer RI, Nelson JD. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis. 1986;5(4):440-3. 94. Liang RH, Yung RW, Chan TK, Chau PY, Lam WK, So SY, et al. Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy. Antimicrob Agents Chemother. 1990;34(2):215-8. 95. McLaughlin FJ, Matthews WJ, Jr., Strieder DJ, Sullivan B, Goldmann DA. Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis. J Antimicrob Chemother. 1983;11 Suppl B:195-203.

 96. Muder RR, Boldin M, Brennen C, Hsieh M, Vickers RM, Mitchum K, et al. A controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J Antimicrob Chemother. 1994;34(1):189-90. 97. Padoan R, Cambisano W, Costantini D, Crossignani RM, Danza ML, Trezzi G, et al. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatr Infect Dis J. 1987;6(7):648-53. 98. Schaad UB, Wedgwood J, Ruedeberg A, Kraemer R, Hampel B. Ciprofloxacin as antipseudomonal treatment in patients with cystic fibrosis. Pediatr Infect Dis J. 1128 1997;16(1):106-11; discussion 23-6. 99. Shawky D, Salamah AM, Abd-Elsalam SM, Habba E, Elnaggar MH, Elsawy AA, et al. Nitazoxanide-based therapeutic regimen as a novel treatment for Helicobacter pylori infection in children and adolescents: a randomized trial. Eur Rev Med Pharmacol Sci. 2022;26(9):3132-7. 100. Sun Y, Fan J, Chen G, Chen X, Du X, Wang Y, et al. A phase III, multicenter, double-blind, randomized clinical trial to evaluate the efficacy and safety of ceftolozane/tazobactam plus metronidazole versus meropenem in Chinese participants with complicated intra-abdominal infections. International Journal of Infectious Diseases. 2022;123:157-65. 101. Carbon C, Auboyer C, Becq-Giraudon B, Bertrand P, Gallais H, Mouton Y, et al. 1139 Cefotaxime (C) vs cefotaxime + amikacin $(C + A)$ in the treatment of septicemia due to enterobacteria: a multicenter study. Chemioterapia. 1987;6(2 Suppl):367-8. 102. Cone LA, Woodard DR, Stoltzman DS, Byrd RG. Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. Antimicrob Agents Chemother. 1985;28(1):33-6. 103. Croce MA, Fabian TC, Stewart RM, Pritchard FE, Minard G, Trenthem L, et al. Empiric monotherapy versus combination therapy of nosocomial pneumonia in trauma patients. J Trauma. 1993;35(2):303-9; discussion 9-11. 104. Gribble MJ, Chow AW, Naiman SC, Smith JA, Bowie WR, Sacks SL, et al. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin- aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother. 1983;24(3):388-93. 105. Iakovlev SV, Iakovlev VP, Derevianko, II, Kira EF. [Multicenter open randomized trial of meropenem in comparison to ceftazidime and amikacin used in combination in severe hospital infections]. Antibiot Khimioter. 1998;43(1):15-23. 106. Klastersky J, Cappel R, Daneau D. Therapy with carbenicillin and gentamicin for patients with cancer and severe infections caused by gram-negative rods. Cancer. 1973;31(2):331-6. 107. Mandell LA, Nicolle LE, Ronald AR, Landis SJ, Duperval R, Harding GK, et al. A prospective randomized trial of ceftazidime versus cefazolin/tobramycin in the treatment of hospitalized patients with pneumonia. J Antimicrob Chemother. 1987;20(1):95-107. 108. Sculier JP, Coppens L, Klastersky J. Effectiveness of mezlocillin and endotracheally administered sisomicin with or without parenteral sisomicin in the treatment of Gram-negative bronchopneumonia. J Antimicrob Chemother. 1982;9(1):63-

8.

- 109. Randomized multicenter clinical trial with imipenem/cilastatin versus
- cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections.
- German and Austrian Imipenem/Cilastatin Study Group. Eur J Clin Microbiol Infect Dis.
- 1992;11(8):683-92.